Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation (ARISTOTLE)
5 de junio de 2018 actualizado por: Bristol-Myers Squibb
A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation
The trial seeks to determine if apixaban, an investigational anticoagulant (blood-thinner) is as effective as standard therapy (warfarin) in preventing stroke and systemic embolism in subjects with atrial fibrillation and risk factors for stroke.
Descripción general del estudio
Estado
Terminado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Intervencionista
Inscripción (Actual)
20976
Fase
- Fase 3
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
-
Aachen, Alemania, 52074
- Local Institution
-
Bad Krozingen, Alemania, 79189
- Local Institution
-
Bad Neustadt/ Salle, Alemania, 97616
- Local Institution
-
Bad Oeynhausen, Alemania, 32545
- Local Institution
-
Berlin, Alemania, 13353
- Local Institution
-
Berlin, Alemania, 14050
- Local Institution
-
Berlin, Alemania, 10787
- Local Institution
-
Berlin, Alemania, 10789
- Local Institution
-
Berlin, Alemania, 12043
- Local Institution
-
Berlin-Kopenick, Alemania, 12559
- Local Institution
-
Betzdorf, Alemania, 57518
- Local Institution
-
Bochum, Alemania, 44791
- Local Institution
-
Bochum, Alemania, 44789
- Local Institution
-
Bonn, Alemania, 53127
- Local Institution
-
Coburg, Alemania, 96450
- Local Institution
-
Dillingen, Alemania, 66763
- Local Institution
-
Dresden, Alemania, 01099
- Local Institution
-
Duisburg, Alemania, 47139
- Local Institution
-
Essen, Alemania, 45122
- Local Institution
-
Frankfurt Am Main, Alemania, 60594
- Local Institution
-
Gottingen, Alemania, 37075
- Local Institution
-
Halle/Saale, Alemania, 06120
- Local Institution
-
Hannover, Alemania, 30625
- Local Institution
-
Heidelberg, Alemania, 69120
- Local Institution
-
Heidelberg, Alemania, 69115
- Local Institution
-
Kassel, Alemania, 34121
- Local Institution
-
Lahr, Alemania, 77933
- Local Institution
-
Ludwigshafen, Alemania, 67063
- Local Institution
-
Ludwigshafen, Alemania, 67073
- Local Institution
-
Mannheim, Alemania, 68167
- Local Institution
-
Marburg, Alemania, 35043
- Local Institution
-
Munchen, Alemania, 81675
- Local Institution
-
Munchen, Alemania, 80636
- Local Institution
-
Munchen, Alemania, 81545
- Local Institution
-
Osnabruck, Alemania, 49076
- Local Institution
-
Regensburg, Alemania, 93053
- Local Institution
-
Riesa, Alemania, D-01587
- Local Institution
-
Rostiock, Alemania, 18057
- Local Institution
-
Trier, Alemania, 54292
- Local Institution
-
Waren, Alemania, 17192
- Local Institution
-
Witten, Alemania, 58455
- Local Institution
-
Wolmirstedt, Alemania, 39326
- Local Institution
-
Worms, Alemania, 67550
- Local Institution
-
-
-
-
-
Buenos Aires, Argentina, 1119
- Local Institution
-
Buenos Aires, Argentina, C1280AEB
- Local Institution
-
Buenos Aires, Argentina, 1181
- Local Institution
-
Buenos Aires, Argentina, C1426ANZ
- Local Institution
-
Buenos Aires, Argentina, 1280
- Local Institution
-
Cordoba, Argentina, 5000
- Local Institution
-
Cordoba, Argentina, X5000EPU
- Local Institution
-
Cordoba, Argentina, X5008KKF
- Local Institution
-
Cordoba, Argentina, X5003DCE
- Local Institution
-
Salta, Argentina, 4400
- Local Institution
-
Santa Fe, Argentina, 3000
- Local Institution
-
Tucuman, Argentina, T4000NIL
- Local Institution
-
-
Buenos Aires
-
Adrogue, Buenos Aires, Argentina, 1846
- Local Institution
-
Bahia Blanca, Buenos Aires, Argentina, B8000FTD
- Local Institution
-
Ciudad Autonoma, Buenos Aires, Argentina, CP1425A WC
- Local Institution
-
Ciudad Autonoma, Buenos Aires, Argentina, 1128AAD
- Local Institution
-
Ciudad Autonoma, Buenos Aires, Argentina, 1128
- Local Institution
-
Ciudad Autonoma, Buenos Aires, Argentina, 1426 EGR
- Local Institution
-
Ciudad Autonoma, Buenos Aires, Argentina, C1426 EGR
- Local Institution
-
Ciudad Autonoma, Buenos Aires, Argentina, CP1425AWC
- Local Institution
-
Ciudad Autonoma De, Buenos Aires, Argentina, 1180
- Local Institution
-
Ciudad Autonoma De Buenos Aire, Buenos Aires, Argentina, CI094AAD
- Local Institution
-
Coronel Suarez, Buenos Aires, Argentina, B7540GHD
- Local Institution
-
Haedo, Buenos Aires, Argentina, B1706AJU
- Local Institution
-
Junin, Buenos Aires, Argentina, 6000
- Local Institution
-
La Plata, Buenos Aires, Argentina, 1900
- Local Institution
-
La Plata, Buenos Aires, Argentina, B1900AXI
- Local Institution
-
La Plata, Buenos Aires, Argentina, 1902
- Local Institution
-
Mar Del Plata, Buenos Aires, Argentina, 7600
- Local Institution
-
Merlo, Buenos Aires, Argentina, B1722COV
- Local Institution
-
Merlo, Buenos Aires, Argentina, 1722
- Local Institution
-
Olivos, Buenos Aires, Argentina, 1602
- Local Institution
-
Quilmes, Buenos Aires, Argentina, 1878
- Local Institution
-
Ramos Mejia, Buenos Aires, Argentina, B1704ESN
- Local Institution
-
Ramos Mejia, Buenos Aires, Argentina, B1704ETD
- Local Institution
-
Ramos Mejia, Buenos Aires, Argentina, 1706
- Local Institution
-
San Justo, Buenos Aires, Argentina, 1754
- Local Institution
-
San Martin, Buenos Aires, Argentina, 1650
- Local Institution
-
San Nicolas, Buenos Aires, Argentina, 2900
- Local Institution
-
Zarate, Buenos Aires, Argentina, 2800
- Local Institution
-
Zarate, Buenos Aires, Argentina, B2800DGH
- Local Institution
-
-
Provincia DE Cordoba
-
Cordoba, Provincia DE Cordoba, Argentina, 5000
- Local Institution
-
-
RIO Negro
-
Cipolletti, RIO Negro, Argentina, 8324
- Local Institution
-
-
Santa FE
-
Rosario, Santa FE, Argentina, 2000
- Local Institution
-
Rosario, Santa FE, Argentina, S2000CVB
- Local Institution
-
Rosario, Santa FE, Argentina, S2001ODA
- Local Institution
-
-
Santa Fe
-
Rosario, Santa Fe, Argentina, S2000CVD
- Local Institution
-
Rosario, Santa Fe, Argentina, S2000 CVD
- Local Institution
-
-
Tucuman
-
San Miquel De Tucuman, Tucuman, Argentina, 4000
- Local Institution
-
-
-
-
New South Wales
-
Coffs Harbour, New South Wales, Australia, 2450
- Local Institution
-
Concord, New South Wales, Australia, 2139
- Local Institution
-
Gosford, New South Wales, Australia, 2250
- Local Institution
-
Kogarah, New South Wales, Australia, 2217
- Local Institution
-
Miranda, New South Wales, Australia, 2228
- Local Institution
-
-
Queensland
-
Auchenflower, Queensland, Australia, 4066
- Local Institution
-
Brisbane, Queensland, Australia, 4032
- Local Institution
-
Caboolture, Queensland, Australia, 4510
- Local Institution
-
Herston, Queensland, Australia, 4029
- Local Institution
-
Kippa Ring, Queensland, Australia, 4021
- Local Institution
-
Nambour, Queensland, Australia, 4560
- Local Institution
-
Sherwood, Queensland, Australia, 4075
- Local Institution
-
-
South Australia
-
Adelaide, South Australia, Australia, SA 5000
- Local Institution
-
Ashford, South Australia, Australia, 5035
- Local Institution
-
Bedford Park, South Australia, Australia, 5042
- Local Institution
-
Woodville, South Australia, Australia, 5011
- Local Institution
-
-
Victoria
-
Box Hill, Victoria, Australia, 3128
- Local Institution
-
Dandenong, Victoria, Australia, 3175
- Local Institution
-
Geelong, Victoria, Australia, 3220
- Local Institution
-
-
Western Australia
-
Fremantle, Western Australia, Australia, 6160
- Local Institution
-
Joondalup, Western Australia, Australia, 6027
- Local Institution
-
-
-
-
-
Graz, Austria, 8036
- Local Institution
-
Oberpullendorf, Austria, 7350
- Local Institution
-
Vienna, Austria, 1160
- Local Institution
-
-
-
-
-
Rio De Janeiro, Brasil, 20551
- Local Institution
-
Rio De Janeiro, Brasil, 20551-030
- Local Institution
-
Rio De Janeiro, Brasil, 22251-030
- Local Institution
-
Rio De Janeiro, Brasil, 22251
- Local Institution
-
Sao Paulo, Brasil, 01323-010
- Local Institution
-
Sao Paulo, Brasil, 01323
- Local Institution
-
Sao Paulo, Brasil, 04012
- Local Institution
-
Sao Paulo, Brasil, 04024-002
- Local Institution
-
Sao Paulo, Brasil, 04038
- Local Institution
-
Sao Paulo, Brasil, 01221-900
- Local Institution
-
Sao Paulo, Brasil, 01221
- Local Institution
-
Sao Paulo, Brasil, 01322-001
- Local Institution
-
Sao Paulo, Brasil, 01322
- Local Institution
-
Sao Paulo, Brasil, 01323-001
- Local Institution
-
Sao Paulo, Brasil, 04012-180
- Local Institution
-
Sao Paulo, Brasil, 04024
- Local Institution
-
Sao Paulo, Brasil, 04038-031
- Local Institution
-
Sao Paulo, Brasil, 08270-070
- Local Institution
-
Sao Paulo, Brasil, 08270
- Local Institution
-
-
Bahia
-
Salvador, Bahia, Brasil, 40144
- Local Institution
-
Salvador, Bahia, Brasil, 41810
- Local Institution
-
Salvador, Bahia, Brasil, 40144-900
- Local Institution
-
Salvador, Bahia, Brasil, 41810-010
- Local Institution
-
-
Minas Gerais
-
Belo Horzonte, Minas Gerais, Brasil, 30150-221
- Local Institution
-
Belo Horzonte, Minas Gerais, Brasil, 30150
- Local Institution
-
Juiz De Fora, Minas Gerais, Brasil, 36021-630
- Local Institution
-
Juiz De Fora, Minas Gerais, Brasil, 36021
- Local Institution
-
Uberaba, Minas Gerais, Brasil, 38056 055
- Local Institution
-
Uberlandia, Minas Gerais, Brasil, 38400-299
- Local Institution
-
Uberlandia, Minas Gerais, Brasil, 38400
- Local Institution
-
-
Para
-
Belem, Para, Brasil, 66087-660
- Local Institution
-
Belem, Para, Brasil, 66087
- Local Institution
-
-
Parana
-
Campina Grande Do Sul, Parana, Brasil, 83430-000
- Local Institution
-
Campina Grande Do Sul, Parana, Brasil, 83430
- Local Institution
-
Curitiba, Parana, Brasil, 80010
- Local Institution
-
Curitiba, Parana, Brasil, 80730
- Local Institution
-
Curitiba, Parana, Brasil, 80010-030
- Local Institution
-
Curitiba, Parana, Brasil, 80730-150
- Local Institution
-
Londrina, Parana, Brasil, 86010-450
- Local Institution
-
Londrina, Parana, Brasil, 86010
- Local Institution
-
-
RIO Grande DO Norte
-
Natal, RIO Grande DO Norte, Brasil, 59020-100
- Local Institution
-
-
RIO Grande DO SUL
-
Porte Alegre, RIO Grande DO SUL, Brasil, 90610-000
- Local Institution
-
Porte Alegre, RIO Grande DO SUL, Brasil, 90880-480
- Local Institution
-
Porto Alegre, RIO Grande DO SUL, Brasil, 90035-903
- Local Institution
-
Porto Alegre, RIO Grande DO SUL, Brasil, 90020-090
- Local Institution
-
Porto Alegre, RIO Grande DO SUL, Brasil, 90620-001
- Local Institution
-
Porto Alegre, RIO Grande DO SUL, Brasil, 91350-280
- Local Institution
-
-
Rio Grande Do Norte
-
Natal, Rio Grande Do Norte, Brasil, 59020
- Local Institution
-
-
Rio Grande Do Sul
-
Porte Alegre, Rio Grande Do Sul, Brasil, 90610
- Local Institution
-
Porte Alegre, Rio Grande Do Sul, Brasil, 90880480
- Local Institution
-
Porto Alegre, Rio Grande Do Sul, Brasil, 90035
- Local Institution
-
Porto Alegre, Rio Grande Do Sul, Brasil, 90020
- Local Institution
-
Porto Alegre, Rio Grande Do Sul, Brasil, 90620
- Local Institution
-
Porto Alegre, Rio Grande Do Sul, Brasil, 91350
- Local Institution
-
-
SAO Paulo
-
Botucatu, SAO Paulo, Brasil, 18618-000
- Local Institution
-
Campinas, SAO Paulo, Brasil, 13059-740
- Local Institution
-
Marilia, SAO Paulo, Brasil, 17515-000
- Local Institution
-
Marilia, SAO Paulo, Brasil, 17515-460
- Local Institution
-
Marilia, SAO Paulo, Brasil, 17519-000
- Local Institution
-
San Jose Do Rio Preto, SAO Paulo, Brasil, 15090-000
- Local Institution
-
Santo Andre, SAO Paulo, Brasil, 09190-610
- Local Institution
-
Sao Jose Do Rio Preto, SAO Paulo, Brasil, 15015-750
- Local Institution
-
Sao Jose Do Rio Preto, SAO Paulo, Brasil, 15015-210
- Local Institution
-
-
Santa Catarina
-
Blumenau, Santa Catarina, Brasil, 89010
- Local Institution
-
Blumenau, Santa Catarina, Brasil, 89010-500
- Local Institution
-
Sao Jose, Santa Catarina, Brasil, 88103
- Local Institution
-
Sao Jose, Santa Catarina, Brasil, 88103-450
- Local Institution
-
-
Sao Paulo
-
Botucatu, Sao Paulo, Brasil, 18618
- Local Institution
-
Campinas, Sao Paulo, Brasil, 13059
- Local Institution
-
Marilia, Sao Paulo, Brasil, 17519
- Local Institution
-
Marilia, Sao Paulo, Brasil, 17515
- Local Institution
-
San Jose Do Rio Preto, Sao Paulo, Brasil, 15090
- Local Institution
-
Santo Andre, Sao Paulo, Brasil, 09190
- Local Institution
-
Sao Jose Do Rio Preto, Sao Paulo, Brasil, 15015
- Local Institution
-
-
-
-
-
Aalst, Bélgica, 9300
- Local Institution
-
Antwerpen, Bélgica, 2020
- Local Institution
-
Antwerpen, Bélgica, 2060
- Local Institution
-
Arlon, Bélgica, 6700
- Local Institution
-
Brugge, Bélgica, 8000
- Local Institution
-
Brussels, Bélgica, 1090
- Local Institution
-
Dillingen, Bélgica, 66763
- Local Institution
-
Genk, Bélgica, 3600
- Local Institution
-
Gent, Bélgica, 9000
- Local Institution
-
Gilly, Bélgica, 6060
- Local Institution
-
Hasselt, Bélgica, 3500
- Local Institution
-
Huy, Bélgica, 4500
- Local Institution
-
Kortrijk, Bélgica, 8500
- Local Institution
-
Menen, Bélgica, 8930
- Local Institution
-
Mol, Bélgica, 2400
- Local Institution
-
Montegnee, Bélgica, 4420
- Local Institution
-
Verviers, Bélgica, 4800
- Local Institution
-
Woluwe- Saint Lambert, Bélgica, 1200
- Local Institution
-
Yvoir, Bélgica, 5530
- Local Institution
-
-
-
-
-
Quebec, Canadá, G1J 1Z6
- Local Institution
-
-
Alberta
-
Calgary, Alberta, Canadá, T2E 7C5
- Local Institution
-
Edmonton, Alberta, Canadá, T6G 2B7
- Local Institution
-
Edmonton, Alberta, Canadá, T5X 3N5
- Local Institution
-
Edmonton, Alberta, Canadá, TSA 4L8
- Local Institution
-
Edmonton, Alberta, Canadá, T56-3NJ
- Local Institution
-
-
British Columbia
-
Burnaby, British Columbia, Canadá, V5G 1T4
- Local Institution
-
Nanaimo, British Columbia, Canadá, V9R 3G9
- Local Institution
-
New Westminster, British Columbia, Canadá, V3L 3W4
- Local Institution
-
North Vancouver, British Columbia, Canadá, V7N 4M2
- Local Institution
-
Victoria, British Columbia, Canadá, V8R 4R2
- Local Institution
-
-
Manitoba
-
Winnipeg, Manitoba, Canadá, R2V 4W3
- Local Institution
-
-
New Brunswick
-
Bathurst, New Brunswick, Canadá, E2A 4X7
- Local Institution
-
-
Newfoundland and Labrador
-
Mount Pearl, Newfoundland and Labrador, Canadá, A1N 1W7
- Local Institution
-
St Johns, Newfoundland and Labrador, Canadá, A1B 3V6
- Local Institution
-
St. John'S, Newfoundland and Labrador, Canadá, A1A 3R5
- Local Institution
-
St. John'S, Newfoundland and Labrador, Canadá, A1E 2C2
- Local Institution
-
-
Ontario
-
Brampton, Ontario, Canadá, L6Z 4N5
- Local Institution
-
Burlington, Ontario, Canadá, L7M 4Y1
- Local Institution
-
Cambridge, Ontario, Canadá, N1R 7R1
- Local Institution
-
Cambridge, Ontario, Canadá, N1R 6V6
- Local Institution
-
Hamilton, Ontario, Canadá, L8L 2X2
- Local Institution
-
London, Ontario, Canadá, N6G 2V2
- Local Institution
-
Mississauga, Ontario, Canadá, L5B 4A2
- Local Institution
-
Newmarket, Ontario, Canadá, L3Y 5G8
- Local Institution
-
Newmarket, Ontario, Canadá, L3Y 8C3
- Local Institution
-
Niagara Falls, Ontario, Canadá, L2E 7H1
- Local Institution
-
Niagara Falls, Ontario, Canadá, L2E7H1
- Local Institution
-
North Bay, Ontario, Canadá, P1B 2H3
- Local Institution
-
Oshawa, Ontario, Canadá, L1J 2J9
- Local Institution
-
Oshawa, Ontario, Canadá, L1J 2K1
- Local Institution
-
Ottawa, Ontario, Canadá, K1Y 4E9
- Local Institution
-
Ottawa, Ontario, Canadá, K1Y 4W7
- Local Institution
-
Sarnia, Ontario, Canadá, N7T 4X3
- Local Institution
-
Scarborough, Ontario, Canadá, M1B 5N1
- Local Institution
-
Sudbury, Ontario, Canadá, P3E 3B8
- Local Institution
-
Sudbury, Ontario, Canadá, P3C 5K7
- Local Institution
-
Sudbury, Ontario, Canadá, P3E 2N8
- Local Institution
-
Sudbury, Ontario, Canadá, P3C5K7
- Local Institution
-
Toronto, Ontario, Canadá, M9W 4L6
- Local Institution
-
Toronto, Ontario, Canadá, M5B 1W8
- Local Institution
-
Weston, Ontario, Canadá, M9N 1W4
- Local Institution
-
-
Prince Edward Island
-
Charlottetown, Prince Edward Island, Canadá, C1A 5Y9
- Local Institution
-
-
Quebec
-
Drummondville, Quebec, Canadá, J2B 7T1
- Local Institution
-
Greenfield Park, Quebec, Canadá, J4V 2G8
- Local Institution
-
Lachine, Quebec, Canadá, H8S 2E4
- Local Institution
-
Levis, Quebec, Canadá, G6V 4Z5
- Local Institution
-
Longueuil, Quebec, Canadá, J4K 1C8
- Local Institution
-
Longueuil, Quebec, Canadá, J4N 0C9
- Local Institution
-
Longueuil, Quebec, Canadá, J4N 1C2
- Local Institution
-
Montreal, Quebec, Canadá, H3T 1E2
- Local Institution
-
Montreal, Quebec, Canadá, H3A 1A1
- Local Institution
-
Montreal, Quebec, Canadá, H1T 1C8
- Local Institution
-
Montreal, Quebec, Canadá, H2W 1T8
- Local Institution
-
Montreal, Quebec, Canadá, W3R-153
- Local Institution
-
Pointe- Claire, Quebec, Canadá, H9R 3J1
- Local Institution
-
St-Lambert, Quebec, Canadá, J4P 2H4
- Local Institution
-
Ste-Foy, Quebec, Canadá, G1W 4R4
- Local Institution
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canadá, S7L OY7
- Local Institution
-
-
-
-
-
Boskovice, Chequia, 680 21
- Local Institution
-
Brno, Chequia, 625 00
- Local Institution
-
Brno-Malomerice, Chequia, 614 00
- Local Institution
-
Ivancice, Chequia, 664 91
- Local Institution
-
Kladno, Chequia, 272 59
- Local Institution
-
Litomysl, Chequia, 570 14
- Local Institution
-
Mestec Kralove, Chequia, 289 03
- Local Institution
-
Ostrava, Chequia, 70852
- Local Institution
-
Prague 13, Chequia, 158 00
- Local Institution
-
Prague 2, Chequia, 128 08
- Local Institution
-
Pribram, Chequia, 261 01
- Local Institution
-
Usti Nad Orlici, Chequia, 562 18
- Local Institution
-
-
-
-
LOS Lagos
-
Osorno, LOS Lagos, Chile, 5311089
- Local Institution
-
Osorno, LOS Lagos, Chile, 5311523
- Local Institution
-
-
Metropolitana
-
Santiago, Metropolitana, Chile, 7500520
- Local Institution
-
Santiago, Metropolitana, Chile, 7500922
- Local Institution
-
Santiago, Metropolitana, Chile, 8330074
- Local Institution
-
-
Region DE LA Araucania
-
Temuco, Region DE LA Araucania, Chile, 4781176
- Local Institution
-
-
Region De La Araucania
-
Temuco, Region De La Araucania, Chile, 4781156
- Local Institution
-
-
Valparaiso
-
Temuco, Valparaiso, Chile, 4781173
- Local Institution
-
Vina Del Mar, Valparaiso, Chile, 2570017
- Local Institution
-
-
-
-
-
Barranquilla, Colombia
- Local Institution
-
Barranquilla, Colombia, XXXXX
- Local Institution
-
Bogota, Colombia
- Local Institution
-
Bogota, Colombia, 000
- Local Institution
-
Cali, Colombia
- Local Institution
-
Medellin, Colombia
- Local Institution
-
-
Antioquia
-
Medellin, Antioquia, Colombia
- Local Institution
-
-
-
-
-
Busan, Corea, república de, 602-702
- Local Institution
-
Daegu, Corea, república de, 700-712
- Local Institution
-
Daegu, Corea, república de, 705-717
- Local Institution
-
Daejon, Corea, república de, 302-718
- Local Institution
-
Goyang, Corea, república de, 411-706
- Local Institution
-
Gwang Ju, Corea, república de, 501-757
- Local Institution
-
Gyeonggi, Corea, república de, 463-707
- Local Institution
-
Pusan, Corea, república de, 602-739
- Local Institution
-
Scongnam-Si, Corea, república de, 463-712
- Local Institution
-
Seoul, Corea, república de, 110-744
- Local Institution
-
Seoul, Corea, república de, 143-729
- Local Institution
-
Seoul, Corea, república de, 130-709
- Local Institution
-
Suwon, Corea, república de, 443-721
- Local Institution
-
-
Gyeonggi-Do
-
Anyang-Si, Gyeonggi-Do, Corea, república de, 431-070
- Local Institution
-
-
Korea
-
Incheon, Korea, Corea, república de, 400-711
- Local Institution
-
-
-
-
-
Arhus C, Dinamarca, 8000
- Local Institution
-
Esbjerg, Dinamarca, 6700
- Local Institution
-
Frederiksberg, Dinamarca, 2000
- Local Institution
-
Frederikssund, Dinamarca, 3600
- Local Institution
-
Gentofte, Dinamarca, 2900
- Local Institution
-
Haderslev, Dinamarca, 6100
- Local Institution
-
Hellerup, Dinamarca, 2900
- Local Institution
-
Herlev, Dinamarca, 2730
- Local Institution
-
Herning, Dinamarca, 7400
- Local Institution
-
Hillerod, Dinamarca, 3400
- Local Institution
-
Hvidovre, Dinamarca, 2650
- Local Institution
-
Kobenhavn, Dinamarca, 2100
- Local Institution
-
Kolding, Dinamarca, 6000
- Local Institution
-
Odense, Dinamarca, 5000
- Local Institution
-
Silkeborg, Dinamarca, 8600
- Local Institution
-
Slagelse, Dinamarca, 4200
- Local Institution
-
Svendborg, Dinamarca, 5700
- Local Institution
-
-
-
-
-
Albacete, España, 02006
- Local Institution
-
Barcelona, España, 08035
- Local Institution
-
Barcelona, España, 08003
- Local Institution
-
Elda, España, 03600
- Local Institution
-
Figueres, España, 17600
- Local Institution
-
Gerona, España, 17007
- Local Institution
-
Las Palmas, España, 35010
- Local Institution
-
Madrid, España, 28006
- Local Institution
-
Madrid, España, 28046
- Local Institution
-
Madrid, España, 28040
- Local Institution
-
Palma De Mallorca, España, 07010
- Local Institution
-
San Sebastian De Los Reyes, España, 28703
- Local Institution
-
Tarragona, España, 43007
- Local Institution
-
Viladecans, España, 08840
- Local Institution
-
-
Alicante
-
San Juan, Alicante, España, 03550
- Local Institution
-
Torrevieja, Alicante, España, 03186
- Local Institution
-
-
Almeria
-
La Canada, Almeria, España, 04120
- Local Institution
-
-
Galicia
-
Lugo, Galicia, España, 27003
- Local Institution
-
-
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35209
- Cardiovascular Associates, Pc
-
Birmingham, Alabama, Estados Unidos, 35235
- Alabama Internal Medicine Pc
-
Birmingham, Alabama, Estados Unidos, 35235
- Birmingham Heart Clinic P.C.
-
Huntsville, Alabama, Estados Unidos, 35801
- Heart Center, Inc.
-
Mobile, Alabama, Estados Unidos, 36608
- Mobile Heart Specialists, PC
-
Mobile, Alabama, Estados Unidos, 36617
- Clara V. Massey, Md
-
-
Alaska
-
Anchorage, Alaska, Estados Unidos, 99508
- Alaska Heart Institute
-
-
Arizona
-
Phoenix, Arizona, Estados Unidos, 85006
- Internal Medicine Physicians Associates, P.C.
-
Tucson, Arizona, Estados Unidos, 85723
- Southern Arizona VA Health Care System
-
Tucson, Arizona, Estados Unidos, 85710
- Southwest Heart
-
Tucson, Arizona, Estados Unidos, 85745
- Pima Research Foundation
-
-
Arkansas
-
Hot Springs, Arkansas, Estados Unidos, 71913
- Dr. Rajesh Shroff
-
Little Rock, Arkansas, Estados Unidos, 72204
- Mary K. Richards, Md Pa
-
-
California
-
Anaheim, California, Estados Unidos, 92801
- Advanced Clinical Reserach Institute
-
Beverly Hills, California, Estados Unidos, 90210
- Act/Cardiovascular Research Institute
-
Carmichael, California, Estados Unidos, 95608
- Capitol Interventional Cardiology
-
Escondido, California, Estados Unidos, 92025
- Escondido Cardiology Associates, Inc.
-
Healdsburg, California, Estados Unidos, 95448
- William D. Bowden, D.O.
-
La Mesa, California, Estados Unidos, 91942
- La Mesa Cardiac Center, A Medical Group
-
Los Angeles, California, Estados Unidos, 90073
- VA Greater Los Angeles Healthcare System
-
Mission Viejo, California, Estados Unidos, 92691
- Coastal Cardiology
-
Oceanside, California, Estados Unidos, 92056
- Kenneth W. Carr Md
-
Palm Springs, California, Estados Unidos, 92262
- Desert Med Grp Inc, Dba Desert Oasis Healthcare Med Group
-
Rancho Mirage, California, Estados Unidos, 92270
- Desert Cardiology Consultants Medical Group, Inc
-
Sacramento, California, Estados Unidos, 95821
- Northern California Research
-
Sacramento, California, Estados Unidos, 95825
- Sacramento Heart And Vascular Medical Associates
-
Sacramento, California, Estados Unidos, 95819
- Regional Cardiolody Associates
-
Santa Barbara, California, Estados Unidos, 93105
- Arrhythmia Consultants Of The Central Coast Medical Group
-
Santa Rosa, California, Estados Unidos, 95403
- Northern California Medical Associates
-
Vista, California, Estados Unidos, 92083
- Progressive Clinical Research
-
Walnut Creek, California, Estados Unidos, 94598
- Cardivasclular Consultants Medical Group
-
Wildomar, California, Estados Unidos, 92595
- Shiva Heart Center Medical Group
-
-
Colorado
-
Colorado Springs, Colorado, Estados Unidos, 80910
- Electrophysiology Associates, Pc
-
Denver, Colorado, Estados Unidos, 80220
- Denver VA Medical Center
-
Denver, Colorado, Estados Unidos, 80218
- Aurora Denver Cardiology Associates, P.C.
-
Golden, Colorado, Estados Unidos, 80401
- New West Physicians Clinical Research
-
Littleton, Colorado, Estados Unidos, 80120
- South Denver Cardiology Associates PC
-
-
Connecticut
-
Bridgeport, Connecticut, Estados Unidos, 06610
- Bridgeport Hospital
-
Bridgeport, Connecticut, Estados Unidos, 06606
- Connecticut Clinical Research, Llc
-
Guilford, Connecticut, Estados Unidos, 06437
- Cardiology Associates Of New Haven,Pc
-
Norwich, Connecticut, Estados Unidos, 06360
- William W Backus Hospital
-
Norwich, Connecticut, Estados Unidos, 06360
- The William W. Backus Hospital
-
Stamford, Connecticut, Estados Unidos, 06905
- Stamford Therapeutics Consortium
-
Waterbury, Connecticut, Estados Unidos, 06708
- Chase Medical Research, LLC
-
-
Delaware
-
Newark, Delaware, Estados Unidos, 19713
- Alfieri Cardiology
-
-
District of Columbia
-
Washington, District of Columbia, Estados Unidos, 20422
- Washington VA Medical Center
-
Washington, District of Columbia, Estados Unidos, 20037
- George Washington University Medical Faculty Associates
-
-
Florida
-
Atlantis, Florida, Estados Unidos, 33462
- Medical Specialist Of The Palm Beach
-
Aventura, Florida, Estados Unidos, 33180
- Miami International Cardiology Consultants
-
Boca Raton, Florida, Estados Unidos, 33431
- David Charles Mishkel, Md, Pa
-
Clearwater, Florida, Estados Unidos, 33756
- The Heart & Vascular Institute Of Florida
-
Clearwater, Florida, Estados Unidos, 33756
- The Heart And Vascular Institute Of Florida
-
Davie, Florida, Estados Unidos, 33324
- Cardiovascular Specialist Of South Florida
-
Daytona Beach, Florida, Estados Unidos, 32114
- Daytona Heart Group
-
Fort Lauderdale, Florida, Estados Unidos, 33316
- Broward General Medical Center
-
Fort Lauderdale, Florida, Estados Unidos, 33308
- Cardiology Associates Of Fort Lauderdale, P.A.
-
Fort Myers, Florida, Estados Unidos, 33907
- Florida Heart Associates
-
Gainesville, Florida, Estados Unidos, 32605
- Florida Research Network, LLC
-
Hollywood, Florida, Estados Unidos, 33021
- Healthworx
-
Hollywood, Florida, Estados Unidos, 33021
- Luis Tami, Md
-
Inverness, Florida, Estados Unidos, 34452
- Nature Coast Clinical Research
-
Jacksonville, Florida, Estados Unidos, 32216
- Jacksonville Center for Clinical Research
-
Jacksonville, Florida, Estados Unidos, 32216
- Jacksonville Cardiovascular Center
-
Jacksonville, Florida, Estados Unidos, 32258
- Jacksonville Heart Center, Pa
-
Jacksonville, Florida, Estados Unidos, 32204
- St. Vincent'S Ambulatory Care, Inc
-
Jacksonville, Florida, Estados Unidos, 32207
- Jacksonville Heart Center, Pa
-
Jacksonville, Florida, Estados Unidos, 32216
- St. Luke'S Cardiology
-
Jacksonville Beach, Florida, Estados Unidos, 32250
- Jacksonville Heart Center, P.A.
-
Jupiter, Florida, Estados Unidos, 33458
- Cvms Research Institute, Llc
-
Jupiter, Florida, Estados Unidos, 33458
- Ricardo Bedoya, M.D.
-
Melbourne, Florida, Estados Unidos, 32901
- Melbourne Internal Medicine Associates
-
Miami, Florida, Estados Unidos, 33137
- Miami International Cardiology Consultants
-
Miami, Florida, Estados Unidos, 33137-3732
- Miami International Cardiology Consultants
-
Naples, Florida, Estados Unidos, 34119
- Physicians Regional Medical Group
-
Orlando, Florida, Estados Unidos, 32803
- Florida Heart Group
-
Oviedo, Florida, Estados Unidos, 32765
- Alpha Medical Research
-
Pensacola, Florida, Estados Unidos, 32501
- Cardiology Consultants
-
Saint Petersburg, Florida, Estados Unidos, 33709
- The Heart And Vascular Institute Of Florida
-
Sarasota, Florida, Estados Unidos, 34239
- Heart & Vascular Center Research, Inc.
-
Sarasota, Florida, Estados Unidos, 34232
- Niranjan Seshadri, Md
-
Vero Beach, Florida, Estados Unidos, 32960
- Research, Inc.
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30342
- Cardiovascular Specialits, Pc
-
Augusta, Georgia, Estados Unidos, 30901
- Augusta Cardiology Clinic, P.C.
-
Columbus, Georgia, Estados Unidos, 31909
- Columbus Cardiology Associates Pc
-
Columbus, Georgia, Estados Unidos, 31909
- Columbus Cardiology Associates,Pc
-
Covington, Georgia, Estados Unidos, 30014
- Georgia Heart Specialists, L.L.C.
-
Decatur, Georgia, Estados Unidos, 30030
- Atlanta Institute For Medical Research, Inc
-
Gainesville, Georgia, Estados Unidos, 30501
- Northeast Georgia Heart Center, Pc
-
Marietta, Georgia, Estados Unidos, 30060
- Wellstar Cardiovascular Medicine, Pc
-
-
Illinois
-
Aurora, Illinois, Estados Unidos, 60504
- Fox Valley Clinical Research Center, LLC
-
Chicago, Illinois, Estados Unidos, 60611
- Nmff
-
Gurnee, Illinois, Estados Unidos, 60031
- Clinical Investigation Specialists, Inc
-
Maywood, Illinois, Estados Unidos, 60153
- Loyola University Medical Center
-
Normal, Illinois, Estados Unidos, 61761
- Illinois Heart & Lung Research Center, Sc
-
North Chicago, Illinois, Estados Unidos, 60064
- Cpt. James A Lovell Federal Health Care Center
-
-
Indiana
-
Anderson, Indiana, Estados Unidos, 46011
- Community Clinical Research Center
-
Bloomington, Indiana, Estados Unidos, 47403
- Premier Healthcare, Llc
-
Elkhart, Indiana, Estados Unidos, 46514
- Elkhart Clinic, LLC
-
Fort Wayne, Indiana, Estados Unidos, 46804
- Lutheran Medical Group, Llc
-
Fort Wayne, Indiana, Estados Unidos, 46805
- Fort Wayne Cardiology
-
Indianapolis, Indiana, Estados Unidos, 46290
- The Care Group, Llc
-
Indianapolis, Indiana, Estados Unidos, 46290
- The Care Group, Llc.
-
Indianapolis, Indiana, Estados Unidos, 46237
- St Francis Medical Group - Indiana Heart Physicians
-
Michigan City, Indiana, Estados Unidos, 46360
- Dali, Sammi
-
South Bend, Indiana, Estados Unidos, 46601
- Cardiology Associates, Inc.
-
-
Iowa
-
Ames, Iowa, Estados Unidos, 50010
- McFarland Clinic PC
-
-
Kansas
-
Overland Park, Kansas, Estados Unidos, 66209
- Midwest Cardiology Associates , P.C.
-
-
Kentucky
-
Elizabethtown, Kentucky, Estados Unidos, 42701
- Central Cardiology Assoc.
-
Lexington, Kentucky, Estados Unidos, 40504
- New Lexington Clinic, P.S.C.
-
Louisville, Kentucky, Estados Unidos, 40205
- Norton Cardiovascular Associates
-
Louisville, Kentucky, Estados Unidos, 40202
- VA Medical Center
-
Owensboro, Kentucky, Estados Unidos, 42303
- Owensboro Heart & Vascular
-
-
Louisiana
-
Alexandria, Louisiana, Estados Unidos, 71301
- Alexandria Cardiology Clinic
-
Houma, Louisiana, Estados Unidos, 70360
- Cardiovascular Institute of the South
-
Lacombe, Louisiana, Estados Unidos, 70445
- Smith, Patel & Amkieh, Llc
-
Lake Charles, Louisiana, Estados Unidos, 70601
- Imperial Calcasieu Medical Group, Llp
-
Marrero, Louisiana, Estados Unidos, 70072
- Cardiology Center, Llc
-
Shreveport, Louisiana, Estados Unidos, 71105
- Cardiology Associates
-
Slidell, Louisiana, Estados Unidos, 70458
- Louisiana Heart Center
-
Slidell, Louisiana, Estados Unidos, 70458
- Medical Research Inst, Inc
-
Slidell, Louisiana, Estados Unidos, 70458
- Medical Research Institute, Inc
-
Ventura, Louisiana, Estados Unidos, 93003
- Ventura Cardio. Cond. Med. Group, Inc.
-
-
Maine
-
Lewiston, Maine, Estados Unidos, 04240
- Central Maine Heart & Vascular Institute
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21224
- Johns Hopkins Bayview Medical Center
-
Baltimore, Maryland, Estados Unidos, 21237
- Franklin Square Hospital
-
Baltimore, Maryland, Estados Unidos, 21208
- Midatlantic Cardiovascular Associates, Pa
-
Baltimore, Maryland, Estados Unidos, 21237
- Midatlantic Cardiovascular Associates, Pa
-
Baltimore, Maryland, Estados Unidos, 21204
- Midatlantic Cardiovascular Associates, P.A.
-
Baltimore, Maryland, Estados Unidos, 21218
- Midatlantic Cardiovascular Associates, P.A.
-
Baltimore, Maryland, Estados Unidos, 21224-2735
- Johns Hopkins Bayview Medical Center
-
Baltimore, Maryland, Estados Unidos, 21237
- Midatlantic Cardiovascular Associates, P.A.
-
Bel Air, Maryland, Estados Unidos, 21014
- Midatlantic Cardiovascular Associates, Pa
-
Columbia, Maryland, Estados Unidos, 21044
- Cardiovascular Specialists Of Central Maryland, P.A.
-
Reisterstown, Maryland, Estados Unidos, 21136
- Clinical Associates Research
-
Westminster, Maryland, Estados Unidos, 21157
- Midatlantic Cardiovascular Associates, Pa
-
-
Massachusetts
-
Billerica, Massachusetts, Estados Unidos, 01821
- Burlington Medical Associates
-
Boston, Massachusetts, Estados Unidos, 02135
- Caritas St. Elizabeth's Medical Center
-
Burlington, Massachusetts, Estados Unidos, 01805
- Lahey Clinic Medical Center
-
Fall River, Massachusetts, Estados Unidos, 02720
- Neccr Internal Medicine & Cardiology Associates,Llc
-
Haverhill, Massachusetts, Estados Unidos, 01830
- Pentucket Medical Associates
-
Haverhill, Massachusetts, Estados Unidos, 01830-6278
- Pentucket Medical Associates
-
Natick, Massachusetts, Estados Unidos, 01760
- Charles River Medical Associates
-
-
Michigan
-
Alpena, Michigan, Estados Unidos, 49707
- Great Lakes Heart Center Of Alpena
-
Detroit, Michigan, Estados Unidos, 48202
- Henry Ford Hospital
-
Lansing, Michigan, Estados Unidos, 48910
- Thoracic And Cardiovascular Healthcare Foundation
-
Livonia, Michigan, Estados Unidos, 48154
- Advanced Cardiovascular Health Specialists, Pc
-
Petoskey, Michigan, Estados Unidos, 49770
- Michigan Heart And Vascular Specialists
-
Royal Oak, Michigan, Estados Unidos, 48073
- William Beaumont Hospital
-
Ypsilanti, Michigan, Estados Unidos, 48197
- Michigan Heart, P.C.
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55455
- University of Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55417
- Minneapolis VA Medical Center
-
Robbinsdale, Minnesota, Estados Unidos, 55422
- North Memorial Health Care
-
-
Mississippi
-
Olive Branch, Mississippi, Estados Unidos, 38654
- Olive Branch Family Medical Center
-
Tupelo, Mississippi, Estados Unidos, 38801
- Tupelo Neurology Clinic, Pa
-
-
Missouri
-
Columbia, Missouri, Estados Unidos, 65212
- University of Missouri
-
Kansas City, Missouri, Estados Unidos, 64108
- Truman Medical Center
-
Kansas City, Missouri, Estados Unidos, 64111
- Saint Luke's Lipid and Diabetes Research Center
-
-
Nebraska
-
Grand Island, Nebraska, Estados Unidos, 68803
- Internal Medical Associates Of Grand Island, P.C
-
Grand Island, Nebraska, Estados Unidos, 68803-4311
- Internal Medical Associates Of Grand Island, P.C
-
Hastings, Nebraska, Estados Unidos, 68901
- Nebraska Heart Institute
-
-
Nevada
-
Las Vegas, Nevada, Estados Unidos, 89106
- VA Southern Nevada Healthcare System
-
-
New Jersey
-
Berlin, New Jersey, Estados Unidos, 08009
- Comprehensive Clinical Research
-
Elmer, New Jersey, Estados Unidos, 08318
- Cardiovascular Associates Of The Delware Valley, P.A.
-
Haddon Heights, New Jersey, Estados Unidos, 08035
- Cardiovascular Associates Of The Delaware Valley, P.A.
-
Princeton, New Jersey, Estados Unidos, 08540
- Princeton Medical Institute
-
Sewell, New Jersey, Estados Unidos, 08080
- Cardio Assoc Of Del Val, P.A.
-
South Plainfield, New Jersey, Estados Unidos, 07080
- Central New Jersey Cardiology
-
-
New Mexico
-
Albuquerque, New Mexico, Estados Unidos, 87012
- Abq Health Partners, Llc
-
Albuquerque, New Mexico, Estados Unidos, 87131-0001
- University Of New Mexico/University Hospital
-
Albuquerque, New Mexico, Estados Unidos, 87131
- University Of New Mexico/University Hospital
-
-
New York
-
Albany, New York, Estados Unidos, 12205
- Albany Associates in Cardiology
-
Albany, New York, Estados Unidos, 12205
- Albany Assoc. In Cardiology
-
Binghamton, New York, Estados Unidos, 13905
- Cardiology Associates, Pc
-
Buffalo, New York, Estados Unidos, 14215
- Buffalo Heart Group, LLP
-
Buffalo, New York, Estados Unidos, 14215-1145
- Buffalo Heart Group, LLP
-
Buffalo, New York, Estados Unidos, 14215
- Bruce L. Platt Md, Pc
-
Buffalo, New York, Estados Unidos, 14215
- Bruce L. Platt, Md
-
East Syracuse, New York, Estados Unidos, 13057
- Heart Care Center, P.C.
-
Huntington, New York, Estados Unidos, 11743
- Huntington Hospital
-
Liverpool, New York, Estados Unidos, 13088
- SJH Cardiology Associates
-
Mineola, New York, Estados Unidos, 11501
- Long Island Heart Associates
-
Saratoga Springs, New York, Estados Unidos, 12866
- Saratoga Cardiology Associates, Pc
-
Williamsville, New York, Estados Unidos, 14221
- Office Of Dr. Kozinn
-
Williamsville, New York, Estados Unidos, 14221
- Suburban Cardiology
-
-
North Carolina
-
Asheville, North Carolina, Estados Unidos, 28803
- Asheville Cardiology Associates
-
Burlington, North Carolina, Estados Unidos, 27215
- Kernodle Clinic, Inc.
-
High Point, North Carolina, Estados Unidos, 27262
- Carolina Cardiology Associates, Pa
-
Pinehurst, North Carolina, Estados Unidos, 28374
- Pinehurst Medical Center, Inc
-
-
North Dakota
-
Fargo, North Dakota, Estados Unidos, 58103
- Lillestol Research LLC
-
-
Ohio
-
Akron, Ohio, Estados Unidos, 44304
- Akron Cardiology Consultants
-
Bucyrus, Ohio, Estados Unidos, 44820
- Christopher M. Johnson, D.O.
-
Bucyrus, Ohio, Estados Unidos, OHIO
- Christopher M. Johnson, D.O.
-
Canal Fulton, Ohio, Estados Unidos, 44614
- Community Health Care, Inc.
-
Canton, Ohio, Estados Unidos, 44710
- Cardiology Associates
-
Cincinnati, Ohio, Estados Unidos, 45219
- The Carl & Edyth Lindner Center For R&E At The Christ Hosp
-
Toledo, Ohio, Estados Unidos, 43608
- Toledo Cardiology Consultants
-
Wadsworth, Ohio, Estados Unidos, 44281
- Family Practice Center Of Wadsworth, Inc.
-
-
Oklahoma
-
Muskogee, Oklahoma, Estados Unidos, 74401
- Jack C. Va Medical Center
-
Oklahoma City, Oklahoma, Estados Unidos, 73104
- University of Oklahoma Health Sciences Center
-
Oklahoma City, Oklahoma, Estados Unidos, 73112
- Plaza Medical Group, Pc
-
Oklahoma City, Oklahoma, Estados Unidos, 73103
- COR Clinical Research, LLC
-
Oklahoma City, Oklahoma, Estados Unidos, 73135
- South Oklahoma Heart Research
-
Oklahoma City, Oklahoma, Estados Unidos, 73120
- Oklahoma Heart Hospital Physicians
-
Oklahoma City, Oklahoma, Estados Unidos, 73139
- Eminence Research, LLC
-
Tulsa, Oklahoma, Estados Unidos, 74136
- Castlerock Clinical Research Consultants, Llc
-
-
Oregon
-
Bend, Oregon, Estados Unidos, 97701
- St. Charles Health System, Inc.
-
Bend, Oregon, Estados Unidos, 97701
- St. Charles Health System, Inc
-
Eugene, Oregon, Estados Unidos, 97401
- Oregon Medical Group - Clinical Research
-
Hillsboro, Oregon, Estados Unidos, 97123
- Hillsboro Cardiology Pc
-
Medford, Oregon, Estados Unidos, 97504
- Rogue Valley Physicians - Clinical Research Group
-
-
Pennsylvania
-
Abington, Pennsylvania, Estados Unidos, 19001
- Abington Medical Specialists
-
Altoona, Pennsylvania, Estados Unidos, 16602
- Blair Medical Associates, Inc.
-
Camp Hill, Pennsylvania, Estados Unidos, 17011
- Heritage Cardiology Assoc.
-
Doylestown, Pennsylvania, Estados Unidos, 18901
- Central Bucks Cardiology
-
Erie, Pennsylvania, Estados Unidos, 16509
- Internal Medicine And Lipid Mgmt.
-
Harrisburg, Pennsylvania, Estados Unidos, 17112
- Kandra, Fierer, Kuskin Associates
-
Hatfield, Pennsylvania, Estados Unidos, 19440
- Pivotal Clinical Research, Llc
-
Jersey Shore, Pennsylvania, Estados Unidos, 17740
- Lycoming Internal Medicine Inc.
-
Sayre, Pennsylvania, Estados Unidos, 18840
- Guthrie Medical Group, P.C.
-
Sayre, Pennsylvania, Estados Unidos, 18840
- Guthrie Clinic Ltd.
-
Uniontown, Pennsylvania, Estados Unidos, 15401
- Preferred Primary Care Physicians
-
West Chester, Pennsylvania, Estados Unidos, 19380
- West Chester Cardiology, Pc
-
Yardley, Pennsylvania, Estados Unidos, 19067
- Cardiology Consultants of Philadelphia
-
-
Rhode Island
-
Providence, Rhode Island, Estados Unidos, 02903
- Rhode Island Hospital
-
-
South Carolina
-
Anderson, South Carolina, Estados Unidos, 29621
- Southeastern Research Associates, Inc
-
Beaufort, South Carolina, Estados Unidos, 29906
- Lowcountry Medical Group, Llc
-
Beaufort, South Carolina, Estados Unidos, 29906
- Lowcountry Medical Group
-
Charleston, South Carolina, Estados Unidos, 29425
- Medical University of South Carolina
-
Columbia, South Carolina, Estados Unidos, 29203
- Columbia Heart Clinic
-
Greenville, South Carolina, Estados Unidos, 29607
- Upstate Cardiology
-
Greer, South Carolina, Estados Unidos, 29650
- Internal Medicine Of Greer
-
Orangeburg, South Carolina, Estados Unidos, 29118
- Palmetto Nephrology Pa
-
Spartanburg, South Carolina, Estados Unidos, 29303
- S. Carolina Pharmaceutical Research
-
-
South Dakota
-
Pierre, South Dakota, Estados Unidos, 57501
- Avera Medical Associates Clinic
-
-
Tennessee
-
Bristol, Tennessee, Estados Unidos, 37620
- Holston Medical Group
-
Kingsport, Tennessee, Estados Unidos, 37660
- Holston Medical Group
-
Knoxville, Tennessee, Estados Unidos, 37920
- Volunteer Research Group
-
Knoxville, Tennessee, Estados Unidos, 37916
- Knoxville Heart Group
-
Knoxville, Tennessee, Estados Unidos, 37920-1502
- Volunteer Research Group
-
Tullahoma, Tennessee, Estados Unidos, 37388
- Tennessee Center For Clinical Trials
-
-
Texas
-
Amarillo, Texas, Estados Unidos, 79106
- Amarillo Heart Clinical Research Institute Inc.
-
Corsicana, Texas, Estados Unidos, 75110
- Corsicana Medical Research, PLLC
-
Dallas, Texas, Estados Unidos, 75226
- Soltero Cardiovascular Research Center
-
Dallas, Texas, Estados Unidos, 75230
- HeartPlace
-
Fort Worth, Texas, Estados Unidos, 76104
- Heart Center of North Texas
-
Houston, Texas, Estados Unidos, 77030
- The Methodist Hospital
-
Houston, Texas, Estados Unidos, 77030
- The University of Texas MD Anderson Cancer Center
-
Houston, Texas, Estados Unidos, 77030
- Center For Atrial Fibrillation
-
Houston, Texas, Estados Unidos, 77030
- The Methodist Hospital Neurology Institute
-
Houston, Texas, Estados Unidos, 77065
- Northwest Houston Cardiology, Pa
-
Houston, Texas, Estados Unidos, 77070
- Northwest Houston Cardiology, Pa
-
Houston, Texas, Estados Unidos, 77074
- Francisco R. Maislos
-
Houston, Texas, Estados Unidos, 77090
- Woodlands North Houston Heart Center
-
Humble, Texas, Estados Unidos, 77338
- Regional Medical Center And Diagnostic Clinics
-
Lackland Air Force Base, Texas, Estados Unidos, 78236
- Wilford Hall Medical Center
-
Lackland Air Force Base, Texas, Estados Unidos, 78236-9908
- Wilford Hall Medical Center
-
Longview, Texas, Estados Unidos, 75605
- DCOL Center for Clinical Research
-
McKinney, Texas, Estados Unidos, 75069
- North Dallas Research Associates
-
Plano, Texas, Estados Unidos, 75093
- North Texas Medical Research
-
Plano, Texas, Estados Unidos, 75024
- Legacy Heart Center
-
San Antonio, Texas, Estados Unidos, 78229
- Covenant Clinical Research, Pa
-
San Antonio, Texas, Estados Unidos, 78217
- Bhs Specialty Network, Inc
-
San Antonio, Texas, Estados Unidos, 78229
- Star Clinical Trails
-
Seguin, Texas, Estados Unidos, 78155
- Edward Balli, Md, Pa
-
Tomball, Texas, Estados Unidos, 77375
- Northwest Heart Center
-
Tyler, Texas, Estados Unidos, 75701
- Tyler Cardiovascular Consultants
-
Tyler, Texas, Estados Unidos, 75708
- University of Texas Health Science Center at Tyler
-
Tyler, Texas, Estados Unidos, 75708
- The Univ. Of Texas Health Science Ctr. At Tyler
-
-
Utah
-
Layton, Utah, Estados Unidos, 84041
- Utah Cardiology P.C
-
-
Virginia
-
Norfolk, Virginia, Estados Unidos, 23510
- Sentara York Clinical Research
-
Richmond, Virginia, Estados Unidos, 23220
- Medical Research Initiatives
-
Roanoke, Virginia, Estados Unidos, 24014
- Roanoke Heart Institute, Plc
-
Virginia Beach, Virginia, Estados Unidos, 23454
- Cardiovascular Associates
-
-
Washington
-
Burien, Washington, Estados Unidos, 98166
- Daniel W. Gottlieb, Md, Ps
-
Burien, Washington, Estados Unidos, 98166
- Daniel William Gottlieb, Md
-
Spokane, Washington, Estados Unidos, 99202
- Rockwood Clinic Research Cent.
-
Walla Walla, Washington, Estados Unidos, 99362
- Walla Walla Clinic
-
-
West Virginia
-
Lewisburg, West Virginia, Estados Unidos, 24901
- Lynn N. Smith, Md
-
-
Wisconsin
-
Green Bay, Wisconsin, Estados Unidos, 54301
- Cardiology Associates Of Green Bay Ltd-Bellin Hospital
-
Madison, Wisconsin, Estados Unidos, 53715
- St. Mary's Hospital
-
Madison, Wisconsin, Estados Unidos, 53715
- St.Mary's Hospital
-
Milwaukee, Wisconsin, Estados Unidos, 53226
- Medical College of Wisconsin
-
Milwaukee, Wisconsin, Estados Unidos, 53215
- Aurora Health Care
-
Waukesha, Wisconsin, Estados Unidos, 53188
- Cardiology Assc. Of Waukesha
-
-
-
-
-
Chelyabinsk, Federación Rusa, 454136
- Local Institution
-
Chita, Federación Rusa, 672090
- Local Institution
-
Dzerzhinskiy, Federación Rusa, 140091
- Local Institution
-
Kazan, Federación Rusa, 420012
- Local Institution
-
Kemerovo, Federación Rusa, 650002
- Local Institution
-
Kirovsk, Federación Rusa, 187342
- Local Institution
-
Krasnodar, Federación Rusa, 350042
- Local Institution
-
Moscow, Federación Rusa, 119992
- Local Institution
-
Moscow, Federación Rusa, 125367
- Local Institution
-
Moscow, Federación Rusa, 109240
- Local Institution
-
Moscow, Federación Rusa, 105229
- Local Institution
-
Moscow, Federación Rusa, 111539
- Local Institution
-
Moscow, Federación Rusa, 115487
- Local Institution
-
Moscow, Federación Rusa, 115093
- Local Institution
-
Moscow, Federación Rusa, 121552
- Local Institution
-
Moscow, Federación Rusa, 117593
- Local Institution
-
Moscow, Federación Rusa, 127018
- Local Institution
-
Moscow, Federación Rusa, 125284
- Local Institution
-
Moscow, Federación Rusa, 111020
- Local Institution
-
Moscow, Federación Rusa, 119121
- Local Institution
-
Moscow, Federación Rusa, 121356
- Local Institution
-
Moscow, Federación Rusa, 117556
- Local Institution
-
Moscow, Federación Rusa, 119048
- Local Institution
-
Moscow, Federación Rusa, 123182
- Local Institution
-
Moscow, Federación Rusa, 125206
- Local Institution
-
Moscow, Federación Rusa, 125424
- Local Institution
-
Moscow, Federación Rusa, 129090
- Local Institution
-
Nizhni Novgorod, Federación Rusa, 603003
- Local Institution
-
Nizhni Novgorod, Federación Rusa, 603005
- Local Institution
-
Novosibirsk, Federación Rusa, 630008
- Local Institution
-
Novosibirsk, Federación Rusa, 630054
- Local Institution
-
Odintsovo, Federación Rusa, 143000
- Local Institution
-
Penza, Federación Rusa, 440026
- Local Institution
-
Perm, Federación Rusa, 614097
- Local Institution
-
Rostov-On-Don, Federación Rusa, 344022
- Local Institution
-
Ryazan, Federación Rusa, 390026
- Local Institution
-
Saint Petersburg, Federación Rusa, 193312
- Local Institution
-
Saint Petersburg, Federación Rusa, 193144
- Local Institution
-
Saint-Petersburg, Federación Rusa, 190103
- Local Institution
-
Saint-Petersburg, Federación Rusa, 191025
- Local Institution
-
Saint-Petersburg, Federación Rusa, 193163
- Local Institution
-
Saint-Petersburg, Federación Rusa, 196601
- Local Institution
-
Saint-Petersburg, Federación Rusa, 198013
- Local Institution
-
Samara, Federación Rusa, 443070
- Local Institution
-
Saratov, Federación Rusa, 410002
- Local Institution
-
St Petersburg, Federación Rusa, 198013
- Local Institution
-
St Petersburg, Federación Rusa, 192288
- Local Institution
-
St-Petersburg, Federación Rusa, 194354
- Local Institution
-
St-Petersburg, Federación Rusa, 195271
- Local Institution
-
St. Petersburg, Federación Rusa, 197341
- Local Institution
-
St. Petersburg, Federación Rusa, 197110
- Local Institution
-
St.-Petersburg, Federación Rusa, 197341
- Local Institution
-
St.Petersburg, Federación Rusa, 199106
- Local Institution
-
Tomsk, Federación Rusa, 634012
- Local Institution
-
Tumen, Federación Rusa, 625023
- Local Institution
-
Tver, Federación Rusa, 170036
- Local Institution
-
Voronezh, Federación Rusa, 394066
- Local Institution
-
Voronezh, Federación Rusa, 394065
- Local Institution
-
Yaroslavl, Federación Rusa, 150030
- Local Institution
-
Yaroslavl, Federación Rusa, 150003
- Local Institution
-
Yaroslavl, Federación Rusa, 150002
- Local Institution
-
Zheleznodorozhniy, Federación Rusa, 143920
- Local Institution
-
Zhukovsky, Federación Rusa, 140160
- Local Institution
-
Zhukovsky, Federación Rusa, 140180
- Local Institution
-
-
-
-
-
Manila, Filipinas, 1000
- Local Institution
-
Manila, Filipinas, 1008
- Local Institution
-
Naga City, Filipinas, 4400
- Local Institution
-
Pasig City, Filipinas, 1600
- Local Institution
-
Quezon, Filipinas, 1100
- Local Institution
-
Quezon City, Filipinas, 1102
- Local Institution
-
San Juan, Filipinas, 1100
- Local Institution
-
-
Ilocos Norte
-
Laoag City, Ilocos Norte, Filipinas, 2900
- Local Institution
-
-
-
-
-
Helsinki, Finlandia, 00280
- Local Institution
-
Helsinki, Finlandia, FI-00280
- Local Institution
-
Hus, Finlandia, 00029
- Local Institution
-
Jyvaskyla, Finlandia, 40100
- Local Institution
-
Kemi, Finlandia, 94100
- Local Institution
-
Oulu, Finlandia, 90100
- Local Institution
-
Pori, Finlandia, 28120
- Local Institution
-
Tampere, Finlandia, 33100
- Local Institution
-
-
-
-
-
Amiens Cedex 1, Francia, 80054
- Local Institution
-
Bordeaux Cedex, Francia, 33075
- Local Institution
-
Brest, Francia, 29609
- Local Institution
-
Grenoble Cedex 09, Francia, 38043
- Local Institution
-
La Seyne Sur Mer, Francia, 83500
- Local Institution
-
Paris Cedex 18, Francia, 75018
- Local Institution
-
Six Fours Les Plages, Francia, 83140
- Local Institution
-
-
-
-
-
Hong Kong, Hong Kong
- Local Institution
-
Shatin, Hong Kong
- Local Institution
-
-
-
-
-
Budapest, Hungría, 1125
- Local Institution
-
Budapest, Hungría, 1023
- Local Institution
-
Budapest, Hungría, 1032
- Local Institution
-
Budapest, Hungría, 1096
- Local Institution
-
Budapest, Hungría, 1085
- Local Institution
-
Debrecen, Hungría, 4032
- Local Institution
-
Dunaujvaros, Hungría, 2400
- Local Institution
-
Gyor, Hungría, 9023
- Local Institution
-
Gyula, Hungría, 5700
- Local Institution
-
Hodmezovasarhely, Hungría, 6800
- Local Institution
-
Komarom, Hungría, 2921
- Local Institution
-
Mosonmagyarovar, Hungría, 9200
- Local Institution
-
Oroshaza, Hungría, 5900
- Local Institution
-
Pecs, Hungría, 7624
- Local Institution
-
Siofok, Hungría, 8600
- Local Institution
-
Siofok, Hungría, 8601
- Local Institution
-
Sopron, Hungría, 9400
- Local Institution
-
Szentes, Hungría, 6600
- Local Institution
-
Zalaegerszeg, Hungría, 8900
- Local Institution
-
-
-
-
-
Ahmedabad, India, 380014
- Local Institution
-
Annamalainagar, India, 608002
- Local Institution
-
Bangalore, India, 560052
- Local Institution
-
Chennai, India, 600006
- Local Institution
-
Hyderabad, India, 500001
- Local Institution
-
Hyderabad, India, 500044
- Local Institution
-
Indore, India, 452014
- Local Institution
-
Indore, India, 452001
- Local Institution
-
Kolkata, India, 700054
- Local Institution
-
Kottayam, India, 686016
- Local Institution
-
Lucknow, India, 226003
- Local Institution
-
Mumbai Naka, India, 422005
- Local Institution
-
Nashik, India, 422002
- Local Institution
-
New Delhi, India, 110025
- Local Institution
-
New Delhi, India, 110060
- Local Institution
-
New Delhi, India, 116025
- Local Institution
-
Pune, India, 411001
- Local Institution
-
Pune, India, 411004
- Local Institution
-
Thrissur, India, 680002
- Local Institution
-
Vijayawada, India, 520008
- Local Institution
-
-
Andhra Pradesh
-
Visakhapatnam, Andhra Pradesh, India, 530003
- Local Institution
-
-
Andhrapradesh
-
Visakhapatnam, Andhrapradesh, India, 530002
- Local Institution
-
-
Andra Pradesh
-
Hyderabad, Andra Pradesh, India, 500004
- Local Institution
-
-
Gujarat
-
Ahmedabad, Gujarat, India, 380060
- Local Institution
-
Vadodara, Gujarat, India, 390007
- Local Institution
-
-
Karnataka
-
Bangalore, Karnataka, India, 560054
- Local Institution
-
Bangalore, Karnataka, India, 5600034
- Local Institution
-
Bangalore, Karnataka, India, 560094
- Local Institution
-
Mysore, Karnataka, India, 570004
- Local Institution
-
-
Kerela
-
Calicut, Kerela, India, 673 004
- Local Institution
-
-
Maharashta
-
Pune, Maharashta, India, 411011
- Local Institution
-
-
Maharashtra
-
Nagpur, Maharashtra, India, 440010
- Local Institution
-
Nagpur, Maharashtra, India, 440012
- Local Institution
-
Pune, Maharashtra, India, 411001
- Local Institution
-
Pune, Maharashtra, India, 421006
- Local Institution
-
-
Punjab
-
Jalandhar, Punjab, India, 144008
- Local Institution
-
-
Rajasthan
-
Bikaner, Rajasthan, India, 334001
- Local Institution
-
Bikaner, Rajasthan, India, 334003
- Local Institution
-
-
Uttar Pradesh
-
Lucknow, Uttar Pradesh, India, 226003
- Local Institution
-
-
-
-
-
Afula, Israel, 18101
- Local Institution
-
Ashkelon, Israel, 78306
- Local Institution
-
Givatayim, Israel, 53583
- Local Institution
-
Hadera, Israel, 38100
- Local Institution
-
Haifa, Israel, 31096
- Local Institution
-
Haifa, Israel, 34362
- Local Institution
-
Holon, Israel, 58100
- Local Institution
-
Jerusalem, Israel, 91120
- Local Institution
-
Jerusalem, Israel, 91240
- Local Institution
-
Kfar-Saba, Israel, 44281
- Local Institution
-
Nazareth, Israel, 16100
- Local Institution
-
Nazareth, Israel, 16000
- Local Institution
-
Petach-Tikva, Israel, 49100
- Local Institution
-
Safed, Israel, 13100
- Local Institution
-
Tel Aviv, Israel, 64239
- Local Institution
-
-
-
-
-
Ascoli Piceno, Italia, 63100
- Local Institution
-
Campobasso, Italia, 86100
- Local Institution
-
Chieti, Italia, 66013
- Local Institution
-
Cremona, Italia, 26100
- Local Institution
-
Fidenza (Pr), Italia, 43036
- Local Institution
-
Genova, Italia, 16132
- Local Institution
-
Isernia, Italia, 86170
- Local Institution
-
Livorno, Italia, 57100
- Local Institution
-
Milano, Italia, 20132
- Local Institution
-
Napoli, Italia, 80131
- Local Institution
-
Palermo, Italia, 90127
- Local Institution
-
Reggio Emilia, Italia, 42100
- Local Institution
-
Roma, Italia, 00168
- Local Institution
-
San Daniele De Friuli, Italia, 33038
- Local Institution
-
Torino, Italia, 10153
- Local Institution
-
Vittorio Veneto (Tv), Italia, 31029
- Local Institution
-
-
Lucca
-
Lido Di Camaiore, Lucca, Italia, 55043
- Local Institution
-
-
-
-
-
Fukui, Japón, 9100067
- Local Institution
-
Kagoshima, Japón, 8920822
- Local Institution
-
Kyoto, Japón, 6168152
- Local Institution
-
Nagasaki, Japón, 852-8102
- Local Institution
-
Oita, Japón, 8700033
- Local Institution
-
Osaka, Japón, 558-8558
- Local Institution
-
Osaka, Japón, 551-0032
- Local Institution
-
Osaka, Japón, 5510032
- Local Institution
-
Saga, Japón, 8490917
- Local Institution
-
-
Fukuoka
-
Itoshima City, Fukuoka, Japón, 819-1104
- Local Institution
-
Kurume, Fukuoka, Japón, 8390863
- Local Institution
-
Ohkawa-City, Fukuoka, Japón, 8310016
- Local Institution
-
-
Fukushima
-
Shirakawa City, Fukushima, Japón, 961-0005
- Local Institution
-
-
Gunma
-
Takasaki City, Gunma, Japón, 3700829
- Local Institution
-
-
Hokkaido
-
Asahikawa-Shi, Hokkaido, Japón, 0788214
- Local Institution
-
Katou-Gun, Hokkaido, Japón, 0800111
- Local Institution
-
Katou-gun, Hokkaido, Japón, 080111
- Local Institution
-
Sapporo-Shi, Hokkaido, Japón, 0028043
- Local Institution
-
Tomakomai-Shi, Hokkaido, Japón, 002-8043
- Local Institution
-
Tomakomai-shi, Hokkaido, Japón, 0028043
- Local Institution
-
Yubari, Hokkaido, Japón, 0680402
- Local Institution
-
-
Hyogo
-
Kobe, Hyogo, Japón, 6540026
- Local Institution
-
-
Kagoshima Prefecture
-
Izumi City, Kagoshima Prefecture, Japón, 8990131
- Local Institution
-
-
Kanagawa
-
Isehara, Kanagawa, Japón, 2591193
- Local Institution
-
Yokohama, Kanagawa, Japón, 2458575
- Local Institution
-
Yokohama City, Kanagawa, Japón, 2278501
- Local Institution
-
Yokosuka, Kanagawa, Japón, 2388567
- Local Institution
-
-
Miyagi
-
Sendai City, Miyagi, Japón, 983-8520
- Local Institution
-
-
Nara
-
Nara City, Nara, Japón, 630-8305
- Local Institution
-
-
Osaka
-
Izumi City, Osaka, Japón, 594-0071
- Local Institution
-
Osaka City, Osaka, Japón, 5330022
- Local Institution
-
Osaka-Shi, Osaka, Japón, 540-0006
- Local Institution
-
Osaka-shi, Osaka, Japón, 5400006
- Local Institution
-
Suita-City, Osaka, Japón, 5658565
- Local Institution
-
Takatsuki City, Osaka, Japón, 5690852
- Local Institution
-
Yao, Osaka, Japón, 5810036
- Local Institution
-
-
Saga
-
Saga City, Saga, Japón, 840-8571
- Local Institution
-
Saga City, Saga, Japón, 849-8501
- Local Institution
-
-
Saitama
-
Kasukabe-Shi, Saitama, Japón, 344-0035
- Local Institution
-
Kasukabe-shi, Saitama, Japón, 3440035
- Local Institution
-
-
Tokyo
-
Itabashi-Ku, Tokyo, Japón, 173-0015
- Local Institution
-
Itabashi-ku, Tokyo, Japón, 1730015
- Local Institution
-
Meguro-Ku, Tokyo, Japón, 153-8515
- Local Institution
-
Meguro-ku, Tokyo, Japón, 1538515
- Local Institution
-
Shinagawa-Ku, Tokyo, Japón, 1428666
- Local Institution
-
-
Toyama
-
Toyama City, Toyama, Japón, 9308550
- Local Institution
-
-
Yamaguchi
-
Iwakuni, Yamaguchi, Japón, 7400021
- Local Institution
-
-
-
-
-
Kuala Lumpur, Malasia, 56000
- Local Institution
-
Kuala Lumpur, Malasia, 59100
- Local Institution
-
-
Kelantan
-
Kubang Kerian, Kelantan, Malasia, 16150
- Local Institution
-
-
Sarawak
-
Kota Samarahan, Sarawak, Malasia, 94300
- Local Institution
-
-
Selangor
-
Batu Caves, Selangor, Malasia, 68100
- Local Institution
-
-
-
-
-
Puebla, México, 11490
- Local Institution
-
Queretaro, México, 76000
- Local Institution
-
-
BAJA California
-
Tijuana, BAJA California, México, 22500
- Local Institution
-
-
Distrito Federal
-
Col. Toriello Guerra, Distrito Federal, México, CP 14050
- Local Institution
-
Mexico City, Distrito Federal, México, 06726
- Local Institution
-
Mexico City, Distrito Federal, México, 14080
- Local Institution
-
Mexico City, Distrito Federal, México, 07760
- Local Institution
-
Mexico City, Distrito Federal, México, 06070
- Local Institution
-
Mexico City, Distrito Federal, México, 10700
- Local Institution
-
-
Jalisco
-
Guadalajara, Jalisco, México, 44200
- Local Institution
-
Guadalajara, Jalisco, México, 44600
- Local Institution
-
Guadalajara, Jalisco, México, 44656
- Local Institution
-
-
Michoacan
-
Morelia, Michoacan, México, 58000
- Local Institution
-
-
Nuevo LEON
-
Monterrey, Nuevo LEON, México, 64710
- Local Institution
-
Monterrey, Nuevo LEON, México, 64000
- Local Institution
-
Monterrey, Nuevo LEON, México, 64700
- Local Institution
-
-
Sinaloa
-
Culiacan, Sinaloa, México, 80020
- Local Institution
-
-
Veracruz
-
Jalapa, Veracruz, México, 91020
- Local Institution
-
-
-
-
-
Alesund, Noruega, 6003
- Local Institution
-
Bergen, Noruega, 5021
- Local Institution
-
Bergen, Noruega, N-5021
- Local Institution
-
Elverum, Noruega, 2408
- Local Institution
-
Flekkefjord, Noruega, 4400
- Local Institution
-
Nesttun, Noruega, 5221
- Local Institution
-
Oslo, Noruega, 0407
- Local Institution
-
Skien, Noruega, 3710
- Local Institution
-
Stavanger, Noruega, 4064
- Local Institution
-
Straume, Noruega, 5353
- Local Institution
-
Tonsberg, Noruega, 3116
- Local Institution
-
Tromso, Noruega, 9038
- Local Institution
-
-
-
-
-
Ankara, Pavo, 06100
- Local Institution
-
Eskisehir, Pavo, 26480
- Local Institution
-
Izmir, Pavo, 35100
- Local Institution
-
-
-
-
-
Breda, Países Bajos, 4818 CK
- Local Institution
-
Deventer, Países Bajos, 7416 SE
- Local Institution
-
Eindhoven, Países Bajos, 5623 EJ
- Local Institution
-
Eindhoven, Países Bajos, 5623EJ
- Local Institution
-
Enschede, Países Bajos, 7513 ER
- Local Institution
-
Hardenberg, Países Bajos, 7772 SE
- Local Institution
-
Hilversum, Países Bajos, 1213 XZ
- Local Institution
-
Nijmegen, Países Bajos, 6525 GA
- Local Institution
-
Oss, Países Bajos, 5342 BT
- Local Institution
-
Rotterdam, Países Bajos, 3045 PM
- Local Institution
-
S-Hertogenbosch, Países Bajos, 5211 NL
- Local Institution
-
Tiel, Países Bajos, 4002 WP
- Local Institution
-
Utrecht, Países Bajos, 3582 KE
- Local Institution
-
Velp, Países Bajos, 6883 AZ
- Local Institution
-
-
-
-
-
Lima, Perú, LIMA 33
- Local Institution
-
Lima, Perú, LIMA 01
- Local Institution
-
Lima, Perú, LIMA 1
- Local Institution
-
-
Callao
-
Bellavista, Callao, Perú, 2176
- Local Institution
-
Bellavista, Callao, Perú, CALLAO 2
- Local Institution
-
-
Lambayeque
-
Chiclayo, Lambayeque, Perú, CIX
- Local Institution
-
-
Lima
-
Jesus Maria, Lima, Perú, 11
- Local Institution
-
Jesus Maria, Lima, Perú, LIMA 11
- Local Institution
-
Miraflores, Lima, Perú, LIMA 18
- Local Institution
-
San Borja, Lima, Perú, LIMA 41
- Local Institution
-
San Martin De Porres, Lima, Perú, LIMA 31
- Local Institution
-
-
-
-
-
Gdynia, Polonia, 81-423
- Local Institution
-
Gdynia, Polonia, 81-472
- Local Institution
-
Gdynia, Polonia, 81-519
- Local Institution
-
Grodzisk Mazowiecki, Polonia, 05-825
- Local Institution
-
Inowroclaw, Polonia, 88-100
- Local Institution
-
Kielce, Polonia, 25-736
- Local Institution
-
Kielce, Polonia, 25-763
- Local Institution
-
Krakow, Polonia, 31-202
- Local Institution
-
Krakow, Polonia, 30-092
- Local Institution
-
Krakow, Polonia, 31-135
- Local Institution
-
Lodz, Polonia, 91-347
- Local Institution
-
Lodz, Polonia, 91347
- Local Institution
-
Piotrkow Trybunalski, Polonia, 97-300
- Local Institution
-
Plock, Polonia, 09-402
- Local Institution
-
Plock, Polonia, 09-400
- Local Institution
-
Plonsk, Polonia, 09-100
- Local Institution
-
Poznan, Polonia, 60-531
- Local Institution
-
Poznan, Polonia, 60479
- Local Institution
-
Ruda Slaska, Polonia, 41-703
- Local Institution
-
Skierniewice, Polonia, 96-100
- Local Institution
-
Slupsk, Polonia, 76-200
- Local Institution
-
Torun, Polonia, 87100
- Local Institution
-
Warszawa, Polonia, 01-138
- Local Institution
-
Warszawa, Polonia, 04-073
- Local Institution
-
Warszawa, Polonia, 04-628
- Local Institution
-
Warszawa, Polonia, 04-749
- Local Institution
-
Wegrow, Polonia, 07100
- Local Institution
-
-
-
-
Beijing
-
Beijing, Beijing, Porcelana, 100050
- Local Institution
-
Beijing, Beijing, Porcelana, 100001
- Local Institution
-
Beijing, Beijing, Porcelana, 100853
- Local Institution
-
Beijing, Beijing, Porcelana, 100020
- Local Institution
-
Beijing, Beijing, Porcelana, 100088
- Local Institution
-
Beijing, Beijing, Porcelana, 100101
- Local Institution
-
-
Gansu
-
Lanzhou, Gansu, Porcelana, 730000
- Local Institution
-
Lanzhou, Gansu, Porcelana, 730030
- Local Institution
-
-
Guangdong
-
Guangzhou, Guangdong, Porcelana, 510080
- Local Institution
-
Guangzhou, Guangdong, Porcelana, 510120
- Local Institution
-
-
Hebei
-
Shijiazhuang, Hebei, Porcelana, 050000
- Local Institution
-
-
Heilongjiang
-
Daqing, Heilongjiang, Porcelana, 163001
- Local Institution
-
Haerbin, Heilongjiang, Porcelana, 150086
- Local Institution
-
Haerbin, Heilongjiang, Porcelana, 150001
- Local Institution
-
-
Hubei
-
Wuhan, Hubei, Porcelana, 430060
- Local Institution
-
-
Hunan
-
Changsha, Hunan, Porcelana, 410000
- Local Institution
-
-
Jiangsu
-
Hangzhou, Jiangsu, Porcelana, 310009
- Local Institution
-
Nanjing, Jiangsu, Porcelana, 210029
- Local Institution
-
-
Liaoning
-
Dalian, Liaoning, Porcelana, 116011
- Local Institution
-
Dalian, Liaoning, Porcelana, 116021
- Local Institution
-
Dalian, Liaoning, Porcelana, 116027
- Local Institution
-
Shenyang, Liaoning, Porcelana, 110016
- Local Institution
-
Shenyang, Liaoning, Porcelana, 110003
- Local Institution
-
-
Shandong
-
Jinan, Shandong, Porcelana, 250012
- Local Institution
-
Jinan, Shandong, Porcelana, 250033
- Local Institution
-
Qingdao, Shandong, Porcelana, 266011
- Local Institution
-
-
Shanghai
-
Shanghai, Shanghai, Porcelana, 200080
- Local Institution
-
Shanghai, Shanghai, Porcelana, 200025
- Local Institution
-
Shanghai, Shanghai, Porcelana, 200433
- Local Institution
-
Shanghai, Shanghai, Porcelana, 200011
- Local Institution
-
Shanghai, Shanghai, Porcelana, 200233
- Local Institution
-
Shanghai, Shanghai, Porcelana, 200003
- Local Institution
-
Shanghai, Shanghai, Porcelana, 100037
- Local Institution
-
Shanghai, Shanghai, Porcelana, 200031
- Local Institution
-
-
Sichuan
-
Chengdu, Sichuan, Porcelana, 610041
- Local Institution
-
Chongqing, Sichuan, Porcelana, 400010
- Local Institution
-
-
Zhejiang
-
Hangzhou, Zhejiang, Porcelana, 310009
- Local Institution
-
-
-
-
-
Cayey, Puerto Rico, 00736
- Local Institution
-
Cidra, Puerto Rico, 00739
- Local Institution
-
Ponce, Puerto Rico, 00717
- Local Institution
-
-
-
-
-
Antrim, Reino Unido, BT41 2RL
- Local Institution
-
Blackpool, Reino Unido, FY3 8NR
- Local Institution
-
Glasgow, Reino Unido, G21 3UW
- Local Institution
-
-
Aberdeenshire
-
Aberdeen, Aberdeenshire, Reino Unido, AB25 2ZN
- Local Institution
-
Glasgow, Aberdeenshire, Reino Unido, G11 6NT
- Local Institution
-
-
Antrim
-
Belfast, Antrim, Reino Unido, BT14 6AB
- Local Institution
-
-
Armagh
-
Craigavon, Armagh, Reino Unido, BT63 5QQ
- Local Institution
-
-
Cambridgeshire
-
Cambridge, Cambridgeshire, Reino Unido, CB2 2QQ
- Local Institution
-
Peterborough, Cambridgeshire, Reino Unido, PE2 5GP
- Local Institution
-
-
Derbyshire
-
Chesterfield, Derbyshire, Reino Unido, S44 5BL
- Local Institution
-
Chesterfield, Derbyshire, Reino Unido, S40 4TF
- Local Institution
-
-
Dorset
-
Bournemouth, Dorset, Reino Unido, BH7 7DW
- Local Institution
-
-
Dumbartonshire
-
Glasgow, Dumbartonshire, Reino Unido, G11 6NT
- Local Institution
-
-
EAST Sussex
-
Chichester, EAST Sussex, Reino Unido, PO19 6SE
- Local Institution
-
-
Essex
-
Colchester, Essex, Reino Unido, C03 4LN
- Local Institution
-
Romford, Essex, Reino Unido, RH7 0AG
- Local Institution
-
-
Greater London
-
Denmark Hill, Greater London, Reino Unido, SE5 9RS
- Local Institution
-
London, Greater London, Reino Unido, SW17 0RE
- Local Institution
-
-
Gwent
-
Newport, Gwent, Reino Unido, NP20 2UB
- Local Institution
-
-
Hertfordshire
-
Barnet, Hertfordshire, Reino Unido, EN5 3DJ
- Local Institution
-
-
MID Glamorgan
-
Cardiff, MID Glamorgan, Reino Unido, CF14 4XW
- Local Institution
-
Llandough, MID Glamorgan, Reino Unido, CF64 2XX
- Local Institution
-
-
Middlesex
-
Harrow, Middlesex, Reino Unido, HA1 3UJ
- Local Institution
-
-
Nottinghamshire
-
Nottingham, Nottinghamshire, Reino Unido, NG5 1PB
- Local Institution
-
Worksop, Nottinghamshire, Reino Unido, S81 OBD
- Local Institution
-
-
Renfrewshire
-
Paisley, Renfrewshire, Reino Unido, PA2 9PN
- Local Institution
-
-
South Yorkshire
-
Barnsley, South Yorkshire, Reino Unido, S75 2EP
- Local Institution
-
Doncaster, South Yorkshire, Reino Unido, DN2 5LT
- Local Institution
-
-
Stirlingshire
-
Stirling, Stirlingshire, Reino Unido, FK8 2AU
- Local Institution
-
-
Strathclyde
-
Glasgow, Strathclyde, Reino Unido, G51 4TF
- Local Institution
-
-
Suffolk
-
Bury St Edmunds, Suffolk, Reino Unido, IP31 2HD
- Local Institution
-
Bury St Edmunds, Suffolk, Reino Unido, IP33 2QZ
- Local Institution
-
Bury St. Edmunds, Suffolk, Reino Unido, IP30 9QU
- Local Institution
-
Ipswich, Suffolk, Reino Unido, IP14 2PU
- Local Institution
-
Ipswich, Suffolk, Reino Unido, IP7 5DN
- Local Institution
-
-
Tyne and Wear
-
Newcastle Upon Tyne, Tyne and Wear, Reino Unido, NE1 4LP
- Local Institution
-
-
WEST Glamorgan
-
Swansea, WEST Glamorgan, Reino Unido, SA6 6NL
- Local Institution
-
-
WEST Lothian
-
Livingston, WEST Lothian, Reino Unido, EH54 6PP
- Local Institution
-
-
WEST Midlands
-
Birmingham, WEST Midlands, Reino Unido, B18 7QH
- Local Institution
-
-
Wiltshire
-
Westbury, Wiltshire, Reino Unido, BA 13 3JD
- Local Institution
-
Westbury, Wiltshire, Reino Unido, BA13 3JD
- Local Institution
-
-
Yorkshire
-
York, Yorkshire, Reino Unido, YO31 8HE
- Local Institution
-
York, Yorkshire, Reino Unido, YO31 HE
- Local Institution
-
-
-
-
-
Baia Mare, Rumania, 430031
- Local Institution
-
Bucharest, Rumania, 011192
- Local Institution
-
Bucharest, Rumania, 020125
- Local Institution
-
Bucharest, Rumania, 050098
- Local Institution
-
Bucharest, Rumania, 021659
- Local Institution
-
Bucharest, Rumania, 030572
- Local Institution
-
Cluj Napoca, Rumania, 400001
- Local Institution
-
Cluj Napoca, Rumania, 400347
- Local Institution
-
Iasi, Rumania, 700503
- Local Institution
-
Oradea, Rumania, 410169
- Local Institution
-
Sibiu, Rumania, 550245
- Local Institution
-
Targu-Mures, Rumania, 540103
- Local Institution
-
Timisoara, Rumania, 300024
- Local Institution
-
Timisoara, Rumania, 300320
- Local Institution
-
Tirgu Mures, Rumania, 540136
- Local Institution
-
-
-
-
-
Singapore, Singapur, 168752
- Local Institution
-
-
-
-
Bloemfontein
-
Westdene, Bloemfontein, Sudáfrica, 9301
- Local Institution
-
-
Cape Town
-
Observatory, Cape Town, Sudáfrica, 7925
- Local Institution
-
-
Gauteng
-
Pretoria, Gauteng, Sudáfrica, 0084
- Local Institution
-
Pretoria, Gauteng, Sudáfrica, 0132
- Local Institution
-
-
KWA ZULU Natal
-
Richards Bay, KWA ZULU Natal, Sudáfrica, 3900
- Local Institution
-
-
Western CAPE
-
Bellville Cape Town, Western CAPE, Sudáfrica, 7530
- Local Institution
-
George, Western CAPE, Sudáfrica, 6529
- Local Institution
-
Parow, Western CAPE, Sudáfrica, 7505
- Local Institution
-
Somerset West, Western CAPE, Sudáfrica, 7130
- Local Institution
-
Worcester, Western CAPE, Sudáfrica, 6850
- Local Institution
-
-
-
-
-
Goteberg, Suecia, 413 45
- Local Institution
-
Helsingborg, Suecia, 251 87
- Local Institution
-
Linkoping, Suecia, 581 85
- Local Institution
-
Lund, Suecia, 222 21
- Local Institution
-
Orebro, Suecia, 70185
- Local Institution
-
Orebro, Suecia, 701 85
- Local Institution
-
Skelleftea, Suecia, 931 86
- Local Institution
-
Stockholm, Suecia, 141 86
- Local Institution
-
Stockholm, Suecia, 171 76
- Local Institution
-
Stockholm, Suecia, 111 57
- Local Institution
-
Stockholm, Suecia, 118 83
- Local Institution
-
Stockholm, Suecia, 111 35
- Local Institution
-
Uppsala, Suecia, 751 85
- Local Institution
-
Vaxjo, Suecia, 351 85
- Local Institution
-
-
-
-
-
Baden, Suiza, 5404
- Local Institution
-
Bern, Suiza, 3010
- Local Institution
-
-
-
-
-
Taipei, Taiwán, 100
- Local Institution
-
Taipei, Taiwán, 112
- Local Institution
-
Taipei, Taiwán, 111
- Local Institution
-
Taipei, Taiwán, 220
- Local Institution
-
Taipei, Taiwán, 10449
- Local Institution
-
Taipei, Taiwán, 104
- Local Institution
-
-
-
-
-
Chernivtsy, Ucrania, 58013
- Local Institution
-
Dnipropetrovsk, Ucrania, 49006
- Local Institution
-
Dnipropetrovsk, Ucrania, 49060
- Local Institution
-
Donetsk, Ucrania, 83045
- Local Institution
-
Donetsk, Ucrania, 83003
- Local Institution
-
Donetsk, Ucrania, 83114
- Local Institution
-
Ivano-Frankivsk, Ucrania, 76025
- Local Institution
-
Kharkiv, Ucrania, 61018
- Local Institution
-
Kharkiv, Ucrania, 61115
- Local Institution
-
Kharkov, Ucrania, 61039
- Local Institution
-
Kharkov, Ucrania, 61002
- Local Institution
-
Kharkov, Ucrania, 61178
- Local Institution
-
Kiev, Ucrania, 01032
- Local Institution
-
Kyiv, Ucrania, 03680
- Local Institution
-
Kyiv, Ucrania, 02091
- Local Institution
-
Kyiv, Ucrania, 03049
- Local Institution
-
Kyiv, Ucrania, 03115
- Local Institution
-
Kyiv, Ucrania, 04050
- Local Institution
-
Kyiv, Ucrania, 04107
- Local Institution
-
Kyiv, Ucrania, 01023
- Local Institution
-
Kyiv, Ucrania, 02660
- Local Institution
-
Kyiv, Ucrania, 01103
- Local Institution
-
Lugansk, Ucrania, 91011
- Local Institution
-
Lugansk, Ucrania, 91016
- Local Institution
-
Lutsk, Ucrania, 43024
- Local Institution
-
Lviv, Ucrania, 79013
- Local Institution
-
Lviv, Ucrania, 79015
- Local Institution
-
Mykolayiv, Ucrania, 54003
- Local Institution
-
Odessa, Ucrania, 65009
- Local Institution
-
Odessa, Ucrania, 65039
- Local Institution
-
Odessa, Ucrania, 65114
- Local Institution
-
Odessa, Ucrania, 65025
- Local Institution
-
Uzhgorod, Ucrania, 88000
- Local Institution
-
Vinnitsa, Ucrania, 21029
- Local Institution
-
Zaporozhye, Ucrania, 69035
- Local Institution
-
Zhytomyr, Ucrania, 10002
- Local Institution
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
- Niño
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
No
Géneros elegibles para el estudio
Todos
Descripción
Inclusion Criteria:
- Males and females ≥ 18 yrs with atrial fibrillation (AF) and one or more of the following risk factors for stroke:
- Age ≥ 75, previous stroke
- transient ischemic attack (TIA) or Systemic Embolism (SE)
- Symptomatic congestive heart failure or left ventricular dysfunction with left ventricular ejection fraction (LVEF) ≤ 40%
- Diabetes mellitus or hypertension requiring pharmacological treatment
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: 2
|
Oral tablets, 5.0 mg or 2.5 mg, twice daily
Otros nombres:
|
|
Comparador activo: 1
|
Oral tablets, 2.0 mg, adjusted to an INR of 2.5 (range 2.0 to 3.0)
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of Participants With First Event of Ischemic/Unspecified Stroke, Hemorrhagic Stroke, or Systemic Embolism (SE) During the Intended Treatment Period
Periodo de tiempo: Time to first event in "Intended Treatment Period": started on day of randomization, ended at efficacy cut-off date (date target number of primary efficacy events [448] was expected to have occurred; set to 30-Jan-2011, prior to unblinding).
|
All suspected efficacy events were adjudicated by the Central Events Committee (CEC).
Diagnosis of stroke=the nontraumatic focal neurological deficit lasting at least 24 hours, and includes ischemic stroke, hemorrhagic stroke, ischemic stroke with hemorrhagic conversion, stroke of uncertain type, and retinal ischemic event (embolism, infarction).
Diagnosis of SE=clinical history consistent with an acute loss of blood flow to a peripheral artery (or arteries), supported by evidence of embolism from surgical specimens, autopsy, angiography, vascular imaging, or other objective testing.
|
Time to first event in "Intended Treatment Period": started on day of randomization, ended at efficacy cut-off date (date target number of primary efficacy events [448] was expected to have occurred; set to 30-Jan-2011, prior to unblinding).
|
|
Rate of Adjudicated Stroke or Systemic Embolism (SE) During the Intended Treatment Period
Periodo de tiempo: "Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
|
Rate=Number of adjudicated stroke or SE events per 100 patient years.
Diagnosis of stroke=the nontraumatic focal neurological deficit lasting at least 24 hours, and includes ischemic stroke, hemorrhagic stroke, ischemic stroke with hemorrhagic conversion, stroke of uncertain type, and retinal ischemic event (embolism, infarction).
Diagnosis of SE=clinical history consistent with an acute loss of blood flow to a peripheral artery (or arteries), supported by evidence of embolism from surgical specimens, autopsy, angiography, vascular imaging, or other objective testing.
|
"Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of Participants With Event of Major (International Society on Thrombosis and Hemostasis [ISTH]) Bleeding During Treatment Period
Periodo de tiempo: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
ISTH Bleeding Criteria: Major bleeding=a bleeding event that was: clinically overt bleeding accompanied by a decrease in hemoglobin (Hgb) of 2 g/dL or more, and/or a transfusion of 2 or more units of packed red blood cells; bleeding that occurred in at least 1 of the following critical sites: intracranial, intraspinal, intraocular (within the corpus of the eye; a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, and retroperitoneal; bleeding that was fatal.
|
"Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
|
Rate of Adjudicated Major (ISTH) Bleed Events During Treatment Period
Periodo de tiempo: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
Rate=number of adjudicated major (ISTH) bleed events per 100 patient years.
ISTH Bleeding Criteria: Major bleeding=a bleeding event that was: clinically overt bleeding accompanied by a decrease in hemoglobin (Hgb) of 2 g/dL or more and/or a transfusion of 2 or more units of packed red blood cells; bleeding that occurred in at least 1 of the following sites: intracranial, intraspinal, intraocular (within the corpus of the eye; a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, and retroperitoneal; bleeding that was fatal.
|
"Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
|
Number of Participants With Events of All-Cause Death During the Intended Treatment Period
Periodo de tiempo: "Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
|
Death was defined as all-cause mortality.
All unobserved deaths were assumed to be cardiovascular in nature unless a non-cardiovascular cause could be clearly provided.
Cardiovascular=deaths due to ischemic and hemorrhagic stroke, SE, myocardial infarction (MI), sudden death, heart failure, other cardiovascular, and unobserved deaths.
Non-cardiovascular=all deaths due to a clearly documented non-cardiovascular cause (further classified into the categories: bleeding, study drug toxicity other than bleeding, malignancy, infection, trauma, and pulmonary causes of death).
|
"Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
|
|
Rate of Adjudicated All-Cause Death During the Intended Treatment Period
Periodo de tiempo: "Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
|
All unobserved deaths were assumed to be cardiovascular in nature unless a non-cardiovascular cause could be clearly provided.
Cardiovascular=deaths due to ischemic and hemorrhagic stroke, SE, MI, sudden death, heart failure, other cardiovascular, and unobserved deaths.
Non-cardiovascular=all deaths due to a clearly documented non-cardiovascular cause (further classified into the categories: bleeding, study drug toxicity other than bleeding, malignancy, infection, trauma, and pulmonary causes of death).
|
"Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
|
|
Rate of Ischemic or Unspecified Stroke, Hemorrhagic Stroke, Systemic Embolism (SE), and Myocardial Infarction (MI) (as Individual Endpoints) During the Intended Treatment Period
Periodo de tiempo: "Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
|
Diagnosis for an acute or evolving MI=elevation of creatine kinase-MB isoenzyme (CK-MB) or Troponin T or I ≥ 2 × the upper limit of normal (ULN), or if no CK-MB or troponin values are available, a total CK ≥ 2×ULN, or new, significant (≥0.04 s) Q waves in ≥2 contiguous leads.
For descriptions of Stroke and SE, see Outcome Measure 1.
|
"Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
|
|
Rate of Ischemic or Unspecified Stroke, Hemorrhagic Stroke, Systemic Embolism (SE), Myocardial Infarction (MI) and All-Cause Death (ACD) (as Composite Endpoints) During the Intended Treatment Period
Periodo de tiempo: "Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
|
Diagnosis for an acute or evolving MI=elevation of CK-MB or Troponin T or I ≥ 2 × the ULN, or if no CK-MB or troponin values are available, a total CK ≥ 2×ULN, or new, significant (≥0.04 s) Q waves in ≥2 contiguous leads.
For descriptions of Stroke and SE, see Outcome Measure 1.
For description of ACD, see Outcome Measure 5.
|
"Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
|
|
Number of Warfarin/Vitamin K Antagonist (VKA) Naive Participants With Composite Stroke / Systemic Embolism (SE) / Major Bleeding During the Intended Treatment Period
Periodo de tiempo: "Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
|
For descriptions of Stroke and SE, see Outcome Measure 1.
For description of Major bleeding, see Outcome Measure 3.
|
"Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
|
|
Rate of Composite Stroke / Systemic Embolism / Major Bleeding in Warfarin/Vitamin K Antagonist (VKA) Naive Participants During the Intended Treatment Period
Periodo de tiempo: "Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
|
"Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
|
|
|
Number of Participants With Events of Major or Clinically Relevant Nonmajor (CRNM) Bleed During Treatment Period
Periodo de tiempo: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
Major bleeding=bleeding that is clinically overt and that either resulted in a decrease in hemoglobin of 2 g/dL or more over a 24-hour period, led to a transfusion of 2 or more units of packed red blood cells, occurred in a critical site, or led to death.
CRNM bleeding=bleeding that is clinically overt, that satisfies none of the additional criteria required for the event to be adjudicated as a major bleeding event, that led to either hospital admission for bleeding, physician-guided medical or surgical treatment for bleeding, or a change in antithrombotic therapy.
|
"Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
|
Rate of Events of Major or Clinically Relevant Non-Major (CRNM) Bleed During Treatment Period
Periodo de tiempo: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
Rate=number of major or CRNM bleed events per 100 patient years.
Major=clinically overt and either 1) resulted in a decrease in hemoglobin of 2 g/dL or more, or 2) led to a transfusion of 2 or more units of packed red blood cells, or 3) occurred in a critical site, or 4) led to death.
CRNM bleeding=clinically overt, but satisfied no additional criteria required to be adjudicated as a major bleeding event, and led to either 1) hospital admission for bleeding or 2) physician guided medical or surgical treatment for bleeding or 3) a change in antithrombotic therapy.
|
"Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
|
Number of Participants With All Bleeding Events During Treatment Period
Periodo de tiempo: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
All bleeding events include major bleeding, CRNM bleeding (see Outcome Measure 12 Description for definitions), plus events of minor bleeding and fatal bleeding.
Minor bleeding: All acute clinically overt bleeding events not meeting the criteria for either major bleeding or clinically relevant non-major bleeding will be classified as minor bleeding.
Fatal bleeding is defined as a bleeding event that the Clinical Events Committee determines is the primary cause of death or contributes directly to death.
|
"Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
|
Rate of All Bleeding Events During Treatment Period
Periodo de tiempo: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
Rate=number of all bleeding events per 100 patient years.
"All bleeding events" include major bleeding, CRNM bleeding (see Outcome Measure 12 Description for definitions), plus events of minor bleeding and fatal bleeding.
Minor bleeding: All acute clinically overt bleeding events not meeting the criteria for either major bleeding or clinically relevant non-major bleeding will be classified as minor bleeding.
Fatal bleeding is defined as a bleeding event that the Clinical Events Committee determines is the primary cause of death or contributes directly to death.
|
"Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of Participants With Adverse Events (AEs), Bleeding AEs, Serious Adverse Events (SAEs), Discontinuations Due to AEs, or Deaths During the Treatment Period
Periodo de tiempo: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
AE: all SAEs or AEs with onset from first dose through 2 days (AEs) or 30 days (SAEs) after the last dose of blinded study drug (BSD).
SAE: all SAEs with onset from first dose through 30 days after the last dose of BSD.
Bleeding AE: all serious or non-serious bleeding-related AEs with onset from first dose through 2 days after the last dose of BSD.
Discontinuations due to AE: all SAEs or AEs with onset from first dose of BSD and with action taken=drug discontinued.
Deaths: all deaths occurring from first dose through 30 days after the last dose of BSD.
|
"Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
|
Rate of Adjudicated Bleeding Endpoints Per Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) During the Treatment Period
Periodo de tiempo: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
Rate=number of adjudicated GUSTO bleeding events per 100 patient years.
GUSTO Bleeding Criteria: GUSTO severe (or life-threatening) bleeding: either intracranial hemorrhage or bleeding that causes hemodynamic compromise and requires intervention.
GUSTO moderate bleeding: bleeding that requires blood transfusion but does not result in hemodynamic compromise.
|
"Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
|
Rate of Adjudicated Bleeding Endpoints Per Thrombolysis in Myocardial Infarction (TIMI) During the Treatment Period
Periodo de tiempo: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
Rate=number of adjudicated TIMI bleeding events per 100 patient years.
TIMI Bleeding Criteria: Major bleeding=Intracranial bleeding and/or clinically overt bleeding associated with ≥5 gm/dL fall in Hgb or 15% fall in hematocrit (Hct) from baseline, accounting for transfusions.
Minor bleeding=Clinically overt bleeding associated with ≥3 gm/dL fall in Hgb or a ≥10% fall in Hct from baseline, accounting for transfusions.
|
"Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
|
Number of Participants With Net-Clinical Benefit During Treatment Period
Periodo de tiempo: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
Net-Clinical Benefit = Composite of stroke, systemic embolism and ISTH major bleeding.
|
"Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
|
Rate of Net-Clinical Benefit During Treatment Period
Periodo de tiempo: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
Rate=number of events of net-clinical benefit per 100 patient years.
Net-Clinical Benefit = Composite of stroke, systemic embolism and ISTH major bleeding
|
"Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Publicaciones y enlaces útiles
La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.
Publicaciones Generales
- Jamieson MJ, Byon W, Dettloff RW, Crawford M, Gargalovic PS, Merali SJ, Onorato J, Quintero AJ, Russ C. Apixaban Use in Obese Patients: A Review of the Pharmacokinetic, Interventional, and Observational Study Data. Am J Cardiovasc Drugs. 2022 Nov;22(6):615-631. doi: 10.1007/s40256-022-00524-x. Epub 2022 May 16.
- Pol T, Hijazi Z, Lindback J, Oldgren J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Granger CB, Lopes RD, Yusuf S, Siegbahn A, Wallentin L. Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation. Cardiovasc Res. 2022 Jul 20;118(9):2112-2123. doi: 10.1093/cvr/cvab262.
- Pol T, Hijazi Z, Lindback J, Alexander JH, Bahit MC, De Caterina R, Eikelboom JW, Ezekowitz MD, Gersh BJ, Granger CB, Hylek EM, Lopes R, Siegbahn A, Wallentin L. Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas. Open Heart. 2021 Mar;8(1):e001471. doi: 10.1136/openhrt-2020-001471.
- Hijazi Z, Wallentin L, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Granger CB, Lopes RD, Pol T, Yusuf S, Oldgren J, Siegbahn A. Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation. J Am Heart Assoc. 2020 Dec 15;9(24):e018984. doi: 10.1161/JAHA.120.018984. Epub 2020 Dec 9.
- Wallentin L, Lindback J, Eriksson N, Hijazi Z, Eikelboom JW, Ezekowitz MD, Granger CB, Lopes RD, Yusuf S, Oldgren J, Siegbahn A. Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation. Eur Heart J. 2020 Nov 1;41(41):4037-4046. doi: 10.1093/eurheartj/ehaa697.
- Hijazi Z, Oldgren J, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Held C, Hylek EM, Lopes RD, Yusuf S, Granger CB, Siegbahn A, Wallentin L; ARISTOTLE and RE-LY Investigators. A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score. Eur Heart J. 2018 Feb 7;39(6):477-485. doi: 10.1093/eurheartj/ehx584.
- Oldgren J, Hijazi Z, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Granger CB, Hylek EM, Lopes RD, Siegbahn A, Yusuf S, Wallentin L; RE-LY and ARISTOTLE Investigators. Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation. Circulation. 2016 Nov 29;134(22):1697-1707. doi: 10.1161/CIRCULATIONAHA.116.022802. Epub 2016 Aug 28.
- Hijazi Z, Oldgren J, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Held C, Hylek EM, Lopes RD, Siegbahn A, Yusuf S, Granger CB, Wallentin L; ARISTOTLE and RE-LY Investigators. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet. 2016 Jun 4;387(10035):2302-2311. doi: 10.1016/S0140-6736(16)00741-8. Epub 2016 Apr 4.
- Hijazi Z, Lindback J, Alexander JH, Hanna M, Held C, Hylek EM, Lopes RD, Oldgren J, Siegbahn A, Stewart RA, White HD, Granger CB, Wallentin L; ARISTOTLE and STABILITY Investigators. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J. 2016 May 21;37(20):1582-90. doi: 10.1093/eurheartj/ehw054. Epub 2016 Feb 25.
- Hijazi Z, Granger CB, Hohnloser SH, Westerbergh J, Lindback J, Alexander JH, Keltai M, Parkhomenko A, Lopez-Sendon JL, Lopes RD, Siegbahn A, Wallentin L. Association of Different Estimates of Renal Function With Cardiovascular Mortality and Bleeding in Atrial Fibrillation. J Am Heart Assoc. 2020 Sep 15;9(18):e017155. doi: 10.1161/JAHA.120.017155. Epub 2020 Aug 31.
- Zeitouni M, Giczewska A, Alexander JH. Reply: Specifics of Dose Modification in ARISTOTLE. J Am Coll Cardiol. 2020 Jul 7;76(1):128-129. doi: 10.1016/j.jacc.2020.05.013. No abstract available.
- Rosjo H, Hijazi Z, Omland T, Westerbergh J, Lyngbakken MN, Alexander JH, Gersh BJ, Granger CB, Hylek EM, Lopes RD, Siegbahn A, Wallentin L. Cardiac troponin is associated with cardiac outcomes in men and women with atrial fibrillation, insights from the ARISTOTLE trial. J Intern Med. 2020 Aug;288(2):248-259. doi: 10.1111/joim.13072. Epub 2020 May 18.
- Zeitouni M, Giczewska A, Lopes RD, Wojdyla DM, Christersson C, Siegbahn A, De Caterina R, Steg PG, Granger CB, Wallentin L, Alexander JH; ARISTOTLE Investigators. Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial. J Am Coll Cardiol. 2020 Mar 17;75(10):1145-1155. doi: 10.1016/j.jacc.2019.12.060.
- Stanifer JW, Pokorney SD, Chertow GM, Hohnloser SH, Wojdyla DM, Garonzik S, Byon W, Hijazi Z, Lopes RD, Alexander JH, Wallentin L, Granger CB. Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease. Circulation. 2020 Apr 28;141(17):1384-1392. doi: 10.1161/CIRCULATIONAHA.119.044059. Epub 2020 Mar 12.
- Garcia DA, Fisher DA, Mulder H, Wruck L, De Caterina R, Halvorsen S, Granger CB, Held C, Wallentin L, Alexander JH, Lopes RD. Gastrointestinal bleeding in patients with atrial fibrillation treated with Apixaban or warfarin: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Am Heart J. 2020 Mar;221:1-8. doi: 10.1016/j.ahj.2019.10.013. Epub 2019 Oct 31.
- Dalgaard F, Mulder H, Wojdyla DM, Lopes RD, Held C, Alexander JH, De Caterina R, Washam JB, Hylek EM, Garcia DA, Gersh BJ, Wallentin L, Granger CB, Al-Khatib SM. Patients With Atrial Fibrillation Taking Nonsteroidal Anti-Inflammatory Drugs and Oral Anticoagulants in the ARISTOTLE Trial. Circulation. 2020 Jan 7;141(1):10-20. doi: 10.1161/CIRCULATIONAHA.119.041296. Epub 2019 Nov 21.
- Goldstein SA, Green J, Huber K, Wojdyla DM, Lopes RD, Alexander JH, Vinereanu D, Wallentin L, Granger CB, Al-Khatib SM. Characteristics and Outcomes of Atrial Fibrillation in Patients With Thyroid Disease (from the ARISTOTLE Trial). Am J Cardiol. 2019 Nov 1;124(9):1406-1412. doi: 10.1016/j.amjcard.2019.07.046. Epub 2019 Aug 7.
- Guimaraes PO, Pokorney SD, Lopes RD, Wojdyla DM, Gersh BJ, Giczewska A, Carnicelli A, Lewis BS, Hanna M, Wallentin L, Vinereanu D, Alexander JH, Granger CB. Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial. Clin Cardiol. 2019 May;42(5):568-571. doi: 10.1002/clc.23178. Epub 2019 Apr 9.
- Washam JB, Hohnloser SH, Lopes RD, Wojdyla DM, Vinereanu D, Alexander JH, Gersh BJ, Hanna M, Horowitz J, Hylek EM, Xavier D, Verheugt FWA, Wallentin L, Granger CB; ARISTOTLE Committees and Investigators. Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial. J Thromb Thrombolysis. 2019 Apr;47(3):345-352. doi: 10.1007/s11239-019-01823-y.
- Hohnloser SH, Fudim M, Alexander JH, Wojdyla DM, Ezekowitz JA, Hanna M, Atar D, Hijazi Z, Bahit MC, Al-Khatib SM, Lopez-Sendon JL, Wallentin L, Granger CB, Lopes RD. Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight. Circulation. 2019 May 14;139(20):2292-2300. doi: 10.1161/CIRCULATIONAHA.118.037955.
- Alexander KP, Brouwer MA, Mulder H, Vinereanu D, Lopes RD, Proietti M, Al-Khatib SM, Hijazi Z, Halvorsen S, Hylek EM, Verheugt FWA, Alexander JH, Wallentin L, Granger CB; ARISTOTLE Investigators. Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial. Am Heart J. 2019 Feb;208:123-131. doi: 10.1016/j.ahj.2018.09.017. Epub 2018 Nov 22.
- Sandhu RK, Ezekowitz JA, Hijazi Z, Westerbergh J, Aulin J, Alexander JH, Granger CB, Halvorsen S, Hanna MS, Lopes RD, Siegbahn A, Wallentin L. Obesity paradox on outcome in atrial fibrillation maintained even considering the prognostic influence of biomarkers: insights from the ARISTOTLE trial. Open Heart. 2018 Nov 1;5(2):e000908. doi: 10.1136/openhrt-2018-000908. eCollection 2018.
- Christersson C, Wallentin L, Andersson U, Alexander JH, Alings M, De Caterina R, Gersh BJ, Granger CB, Halvorsen S, Hanna M, Huber K, Hylek EM, Lopes RD, Oh BH, Siegbahn A. Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation. Heart. 2019 Feb;105(3):235-242. doi: 10.1136/heartjnl-2018-313351. Epub 2018 Sep 12.
- Horowitz JD, De Caterina R, Heresztyn T, Alexander JH, Andersson U, Lopes RD, Steg PG, Hylek EM, Mohan P, Hanna M, Jansky P, Granger CB, Wallentin L; ARISTOTLE Investigators. Asymmetric and Symmetric Dimethylarginine Predict Outcomes in Patients With Atrial Fibrillation: An ARISTOTLE Substudy. J Am Coll Cardiol. 2018 Aug 14;72(7):721-733. doi: 10.1016/j.jacc.2018.05.058.
- Sharma A, Hijazi Z, Andersson U, Al-Khatib SM, Lopes RD, Alexander JH, Held C, Hylek EM, Leonardi S, Hanna M, Ezekowitz JA, Siegbahn A, Granger CB, Wallentin L. Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation. Circulation. 2018 Oct 16;138(16):1666-1676. doi: 10.1161/CIRCULATIONAHA.118.034125.
- Kopin D, Jones WS, Sherwood MW, Wojdyla DM, Wallentin L, Lewis BS, Verheugt FWA, Vinereanu D, Bahit MC, Halvorsen S, Huber K, Parkhomenko A, Granger CB, Lopes RD, Alexander JH. Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial. Am Heart J. 2018 Mar;197:133-141. doi: 10.1016/j.ahj.2017.11.005. Epub 2017 Nov 10.
- Pol T, Held C, Westerbergh J, Lindback J, Alexander JH, Alings M, Erol C, Goto S, Halvorsen S, Huber K, Hanna M, Lopes RD, Ruzyllo W, Granger CB, Hijazi Z. Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial. J Am Heart Assoc. 2018 Feb 1;7(3):e007444. doi: 10.1161/JAHA.117.007444.
- Goto S, Merrill P, Wallentin L, Wojdyla DM, Hanna M, Avezum A, Easton JD, Harjola VP, Huber K, Lewis BS, Parkhomenko A, Zhu J, Granger CB, Lopes RD, Alexander JH. Antithrombotic therapy use and clinical outcomes following thrombo-embolic events in patients with atrial fibrillation: insights from ARISTOTLE. Eur Heart J Cardiovasc Pharmacother. 2018 Apr 1;4(2):75-81. doi: 10.1093/ehjcvp/pvy002.
- Vinereanu D, Wang A, Mulder H, Lopes RD, Jansky P, Lewis BS, Gersh BJ, Avezum A, Hanna M, Held C, Wallentin L, Granger CB, Alexander JH. Outcomes in anticoagulated patients with atrial fibrillation and with mitral or aortic valve disease. Heart. 2018 Aug;104(15):1292-1299. doi: 10.1136/heartjnl-2017-312272. Epub 2018 Jan 19.
- Rao MP, Vinereanu D, Wojdyla DM, Alexander JH, Atar D, Hylek EM, Hanna M, Wallentin L, Lopes RD, Gersh BJ, Granger CB; Apixaban for Reduction in Stroke Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Investigators. Clinical Outcomes and History of Fall in Patients with Atrial Fibrillation Treated with Oral Anticoagulation: Insights From the ARISTOTLE Trial. Am J Med. 2018 Mar;131(3):269-275.e2. doi: 10.1016/j.amjmed.2017.10.036. Epub 2017 Nov 6.
- Vinereanu D, Lopes RD, Mulder H, Gersh BJ, Hanna M, de Barros E Silva PGM, Atar D, Wallentin L, Granger CB, Alexander JH; ARISTOTLE Investigators. Echocardiographic Risk Factors for Stroke and Outcomes in Patients With Atrial Fibrillation Anticoagulated With Apixaban or Warfarin. Stroke. 2017 Dec;48(12):3266-3273. doi: 10.1161/STROKEAHA.117.017574. Epub 2017 Oct 31.
- Hijazi Z, Lindahl B, Oldgren J, Andersson U, Lindback J, Granger CB, Alexander JH, Gersh BJ, Hanna M, Harjola VP, Hylek EM, Lopes RD, Siegbahn A, Wallentin L. Repeated Measurements of Cardiac Biomarkers in Atrial Fibrillation and Validation of the ABC Stroke Score Over Time. J Am Heart Assoc. 2017 Jun 23;6(6):e004851. doi: 10.1161/JAHA.116.004851.
- Lopes RD, Guimaraes PO, Kolls BJ, Wojdyla DM, Bushnell CD, Hanna M, Easton JD, Thomas L, Wallentin L, Al-Khatib SM, Held C, Gabriel Melo de Barros E Silva P, Alexander JH, Granger CB, Diener HC. Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy. Blood. 2017 Jun 1;129(22):2980-2987. doi: 10.1182/blood-2016-08-731638. Epub 2017 Mar 29.
- Cowper PA, Sheng S, Lopes RD, Anstrom KJ, Stafford JA, Davidson-Ray L, Al-Khatib SM, Ansell J, Dorian P, Husted S, McMurray JJV, Steg PG, Alexander JH, Wallentin L, Granger CB, Mark DB. Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial. JAMA Cardiol. 2017 May 1;2(5):525-534. doi: 10.1001/jamacardio.2017.0065.
- Hu PT, Lopes RD, Stevens SR, Wallentin L, Thomas L, Alexander JH, Hanna M, Lewis BS, Verheugt FW, Granger CB, Jones WS. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial. J Am Heart Assoc. 2017 Jan 17;6(1):e004699. doi: 10.1161/JAHA.116.004699.
- Bahit MC, Lopes RD, Wojdyla DM, Held C, Hanna M, Vinereanu D, Hylek EM, Verheugt F, Goto S, Alexander JH, Wallentin L, Granger CB. Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation. Heart. 2017 Apr;103(8):623-628. doi: 10.1136/heartjnl-2016-309901. Epub 2016 Oct 24.
- Alexander JH, Andersson U, Lopes RD, Hijazi Z, Hohnloser SH, Ezekowitz JA, Halvorsen S, Hanna M, Commerford P, Ruzyllo W, Huber K, Al-Khatib SM, Granger CB, Wallentin L; Apixaban for Reduction of Stroke and Other Thromboembolic Complications in Atrial Fibrillation (ARISTOTLE) Investigators. Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2016 Sep 1;1(6):673-81. doi: 10.1001/jamacardio.2016.1829.
- Hijazi Z, Hohnloser SH, Andersson U, Alexander JH, Hanna M, Keltai M, Parkhomenko A, Lopez-Sendon JL, Lopes RD, Siegbahn A, Granger CB, Wallentin L. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial. JAMA Cardiol. 2016 Jul 1;1(4):451-60. doi: 10.1001/jamacardio.2016.1170.
- Jaspers Focks J, Brouwer MA, Wojdyla DM, Thomas L, Lopes RD, Washam JB, Lanas F, Xavier D, Husted S, Wallentin L, Alexander JH, Granger CB, Verheugt FW. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. BMJ. 2016 Jun 15;353:i2868. doi: 10.1136/bmj.i2868.
- Hijazi Z, Aulin J, Andersson U, Alexander JH, Gersh B, Granger CB, Hanna M, Horowitz J, Hylek EM, Lopes RD, Siegbahn A, Wallentin L; ARISTOTLE Investigators. Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation. Heart. 2016 Apr;102(7):508-17. doi: 10.1136/heartjnl-2015-308887. Epub 2016 Feb 2.
- Rao MP, Halvorsen S, Wojdyla D, Thomas L, Alexander JH, Hylek EM, Hanna M, Bahit MC, Lopes RD, De Caterina R, Erol C, Goto S, Lanas F, Lewis BS, Husted S, Gersh BJ, Wallentin L, Granger CB; Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Steering Committee and Investigators. Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. J Am Heart Assoc. 2015 Dec 1;4(12):e002015. doi: 10.1161/JAHA.115.002015. Erratum In: J Am Heart Assoc. 2021 Feb 16;10(4):e014653.
- Vinereanu D, Stevens SR, Alexander JH, Al-Khatib SM, Avezum A, Bahit MC, Granger CB, Lopes RD, Halvorsen S, Hanna M, Husted S, Hylek EM, Margulescu AD, Wallentin L, Atar D. Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial. Eur Heart J. 2015 Dec 7;36(46):3268-75. doi: 10.1093/eurheartj/ehv447. Epub 2015 Sep 14.
- Avezum A, Lopes RD, Schulte PJ, Lanas F, Gersh BJ, Hanna M, Pais P, Erol C, Diaz R, Bahit MC, Bartunek J, De Caterina R, Goto S, Ruzyllo W, Zhu J, Granger CB, Alexander JH. Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. Circulation. 2015 Aug 25;132(8):624-32. doi: 10.1161/CIRCULATIONAHA.114.014807. Epub 2015 Jun 23.
- Held C, Hylek EM, Alexander JH, Hanna M, Lopes RD, Wojdyla DM, Thomas L, Al-Khalidi H, Alings M, Xavier D, Ansell J, Goto S, Ruzyllo W, Rosenqvist M, Verheugt FW, Zhu J, Granger CB, Wallentin L. Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. Eur Heart J. 2015 May 21;36(20):1264-72. doi: 10.1093/eurheartj/ehu463. Epub 2014 Dec 12.
- Hijazi Z, Siegbahn A, Andersson U, Lindahl B, Granger CB, Alexander JH, Atar D, Gersh BJ, Hanna M, Harjola VP, Horowitz J, Husted S, Hylek EM, Lopes RD, McMurray JJ, Wallentin L. Comparison of cardiac troponins I and T measured with high-sensitivity methods for evaluation of prognosis in atrial fibrillation: an ARISTOTLE substudy. Clin Chem. 2015 Feb;61(2):368-78. doi: 10.1373/clinchem.2014.226936. Epub 2014 Dec 1.
- Garcia D, Alexander JH, Wallentin L, Wojdyla DM, Thomas L, Hanna M, Al-Khatib SM, Dorian P, Ansell J, Commerford P, Flaker G, Lanas F, Vinereanu D, Xavier D, Hylek EM, Held C, Verheugt FW, Granger CB, Lopes RD. Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures. Blood. 2014 Dec 11;124(25):3692-8. doi: 10.1182/blood-2014-08-595496. Epub 2014 Oct 15.
- Wallentin L, Hijazi Z, Andersson U, Alexander JH, De Caterina R, Hanna M, Horowitz JD, Hylek EM, Lopes RD, Asberg S, Granger CB, Siegbahn A; ARISTOTLE Investigators. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation. 2014 Nov 18;130(21):1847-58. doi: 10.1161/CIRCULATIONAHA.114.011204. Epub 2014 Oct 7.
- Hijazi Z, Siegbahn A, Andersson U, Granger CB, Alexander JH, Atar D, Gersh BJ, Mohan P, Harjola VP, Horowitz J, Husted S, Hylek EM, Lopes RD, McMurray JJ, Wallentin L; ARISTOTLE Investigators. High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation. 2014 Feb 11;129(6):625-34. doi: 10.1161/CIRCULATIONAHA.113.006286. Epub 2013 Nov 13.
- Flaker G, Lopes RD, Al-Khatib SM, Hermosillo AG, Hohnloser SH, Tinga B, Zhu J, Mohan P, Garcia D, Bartunek J, Vinereanu D, Husted S, Harjola VP, Rosenqvist M, Alexander JH, Granger CB; ARISTOTLE Committees and Investigators. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). J Am Coll Cardiol. 2014 Mar 25;63(11):1082-7. doi: 10.1016/j.jacc.2013.09.062. Epub 2013 Nov 6.
- Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Alexander JH, Atar D, Gersh BJ, Hanna M, Harjola VP, Horowitz JD, Husted S, Hylek EM, Lopes RD, McMurray JJ, Granger CB; ARISTOTLE Investigators. High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin. J Am Coll Cardiol. 2014 Jan 7-14;63(1):52-61. doi: 10.1016/j.jacc.2013.07.093. Epub 2013 Sep 19.
- Alexander JH, Levy E, Lawrence J, Hanna M, Waclawski AP, Wang J, Califf RM, Wallentin L, Granger CB. Documentation of study medication dispensing in a prospective large randomized clinical trial: experiences from the ARISTOTLE Trial. Am Heart J. 2013 Sep;166(3):559-65. doi: 10.1016/j.ahj.2013.05.025. Epub 2013 Aug 15.
- Garcia DA, Wallentin L, Lopes RD, Thomas L, Alexander JH, Hylek EM, Ansell J, Hanna M, Lanas F, Flaker G, Commerford P, Xavier D, Vinereanu D, Yang H, Granger CB. Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. Am Heart J. 2013 Sep;166(3):549-58. doi: 10.1016/j.ahj.2013.05.016. Epub 2013 Jul 25.
- Wallentin L, Lopes RD, Hanna M, Thomas L, Hellkamp A, Nepal S, Hylek EM, Al-Khatib SM, Alexander JH, Alings M, Amerena J, Ansell J, Aylward P, Bartunek J, Commerford P, De Caterina R, Erol C, Harjola VP, Held C, Horowitz JD, Huber K, Husted S, Keltai M, Lanas F, Lisheng L, McMurray JJ, Oh BH, Rosenqvist M, Ruzyllo W, Steg PG, Vinereanu D, Xavier D, Granger CB; Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Investigators. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation. 2013 Jun 4;127(22):2166-76. doi: 10.1161/CIRCULATIONAHA.112.142158. Epub 2013 May 2.
- McMurray JJ, Ezekowitz JA, Lewis BS, Gersh BJ, van Diepen S, Amerena J, Bartunek J, Commerford P, Oh BH, Harjola VP, Al-Khatib SM, Hanna M, Alexander JH, Lopes RD, Wojdyla DM, Wallentin L, Granger CB; ARISTOTLE Committees and Investigators. Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trial. Circ Heart Fail. 2013 May;6(3):451-60. doi: 10.1161/CIRCHEARTFAILURE.112.000143. Epub 2013 Apr 10.
- Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Christersson C, Ezekowitz J, Gersh BJ, Hanna M, Hohnloser S, Horowitz J, Huber K, Hylek EM, Lopes RD, McMurray JJ, Granger CB. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J Am Coll Cardiol. 2013 Jun 4;61(22):2274-84. doi: 10.1016/j.jacc.2012.11.082. Epub 2013 Apr 3.
- Lopes RD, Al-Khatib SM, Wallentin L, Yang H, Ansell J, Bahit MC, De Caterina R, Dorian P, Easton JD, Erol C, Ezekowitz JA, Gersh BJ, Granger CB, Hohnloser SH, Horowitz J, Hylek EM, McMurray JJ, Mohan P, Vinereanu D, Alexander JH. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. Lancet. 2012 Nov 17;380(9855):1749-58. doi: 10.1016/S0140-6736(12)60986-6. Epub 2012 Oct 2. Erratum In: Lancet. 2013 Jan 19;381(9862):204.
- Easton JD, Lopes RD, Bahit MC, Wojdyla DM, Granger CB, Wallentin L, Alings M, Goto S, Lewis BS, Rosenqvist M, Hanna M, Mohan P, Alexander JH, Diener HC; ARISTOTLE Committees and Investigators. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol. 2012 Jun;11(6):503-11. doi: 10.1016/S1474-4422(12)70092-3. Epub 2012 May 8. Erratum In: Lancet Neurol. 2012 Dec;11(12):1021.
- Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 Sep 15;365(11):981-92. doi: 10.1056/NEJMoa1107039. Epub 2011 Aug 27.
Enlaces Útiles
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio (Actual)
31 de diciembre de 2006
Finalización primaria (Actual)
25 de mayo de 2011
Finalización del estudio (Actual)
25 de mayo de 2011
Fechas de registro del estudio
Enviado por primera vez
18 de diciembre de 2006
Primero enviado que cumplió con los criterios de control de calidad
18 de diciembre de 2006
Publicado por primera vez (Estimar)
19 de diciembre de 2006
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
3 de julio de 2018
Última actualización enviada que cumplió con los criterios de control de calidad
5 de junio de 2018
Última verificación
1 de mayo de 2018
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Procesos Patológicos
- Enfermedades cardíacas
- Enfermedades cardiovasculares
- Arritmias Cardiacas
- Fibrilación auricular
- Aleteo auricular
- Mecanismos moleculares de acción farmacológica
- Inhibidores de enzimas
- Inhibidores de la proteasa
- Inhibidores del factor Xa
- Antitrombinas
- Inhibidores de la serina proteinasa
- Anticoagulantes
- Apixabán
- Warfarina
Otros números de identificación del estudio
- CV185-030
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Fibrilación auricular
-
The Second Affiliated Hospital of Chongqing Medical...TerminadoFibrilación auricular | Hipertensión,Esencial | Dilatación atrial izquierdaPorcelana
-
Region SkaneReclutamientoFibrilación auricular | Dilatación atrial izquierdaSuecia
-
Wake Forest University Health SciencesNational Heart, Lung, and Blood Institute (NHLBI)ReclutamientoEnfermedades Renales | Hipertensión | Obesidad Pediátrica | Proteinuria | Albuminuria | Lesión renal | Trastornos de la presión arterial | Disfunción autonómica | Enfermedad renal pediátrica | Disfunción Ventricular Izquierda | Hipertrofia del ventrículo izquierdo | Disfunción renal | Desequilibrio autonómico | Disfunción... y otras condicionesEstados Unidos
Ensayos clínicos sobre warfarin
-
Cairo UniversityReclutamientoComplicaciones maternas después de la anticoagulación oral cuando se inicia temprano y tarde después de la cesárea realizada para pacientes con prótesis de válvula cardíaca mecánicaEgipto